

Replication of the ISAR-REACT 5 Trial in Healthcare Data Claims

NCT 01944800

August 3, 2021

1. RCT Details

This section provides a high-level overview of the RCT that the described real-world evidence study is trying to replicate as closely as possible given the remaining limitations inherent in the healthcare databases.

1.1 Title

Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes ([ISAR-REACT 5](#) trial)

1.2 Intended aim(s)

To compare ticagrelor (180-mg loading dose, 90 mg twice daily thereafter) and prasugrel (60-mg loading dose, 10 mg daily thereafter) for the prevention of cardiovascular events in patients admitted to the hospital with an acute coronary syndrome, with or without ST-segment elevation, who were scheduled to undergo coronary angiography.

1.3 Primary endpoint for replication and RCT finding

The primary outcome was composite of death, myocardial infarction, or stroke at 1 year after randomization

1.4 Required power for primary endpoint and noninferiority margin (if applicable)

Assuming an incidence of 10.0% in ticagrelor users and 12.9% in prasugrel users, 1,895 patients would be required for each group to achieve 80% power to detect a relative risk reduction of 22.5% in the rate of the primary outcome in the ticagrelor group as compared with the prasugrel group, using a two-sided alpha of 0.05.

1.5 Primary trial estimate targeted for replication

HR = 1.36 (95% CI 1.09–1.70) comparing ticagrelor to prasugrel (Schupke et al., 2019)

2. Person responsible for implementation of replication in Aetion

Dureshahwar Jawaid, MPH implemented the study design in the Aetion Evidence Platform. She is not responsible for the validity of the design and analytic choices. All implementation steps are recorded, and the implementation history is archived in the platform.


3. Data Source(s)

Optum, MarketScan

4. Study Design Diagram

The study design diagram visualizes key aspects of the longitudinal study design for expedited review.

Figure 1.



5. Cohort Identification

5.1 Cohort Summary

This study will involve a new user, parallel group, retrospective cohort study design comparing ticagrelor 90 mg twice daily to prasugrel 10 mg daily. The patients will be required to have continuous enrollment during the baseline period of 180 days before initiation of ticagrelor or prasugrel (index date). We will restrict the analyses to patients with an acute coronary syndrome, with or without ST-segment elevation, who were scheduled to undergo coronary angiography.

5.2 Important steps for cohort formation

New use of ticagrelor, exposure, and prasugrel comparator, is defined as no use of either therapy in 180 days prior to index date.

5.2.1 Eligible cohort entry dates

Market availability of ticagrelor in the U.S. started on 2011-07-20.

- For MarketScan: 2011-07-20 to 2018-12-31 (end of data availability).
- For Optum: 2011-07-20 to 2020-03-31 (end of data availability).

5.2.2 Specify inclusion/exclusion criteria for cohort entry and define the index date. Inclusion and exclusion criteria were adapted from the trial as closely as possible. Definitions for all inclusion/exclusion are provided in **Appendix A** and are summarized in the flowcharts below.

5.3 Flowchart of the study cohort assembly

	Optum		MarketScan	
	Less Excluded Patients	Remaining Patients	Less Excluded Patients	Remaining Patients
All patients		78,779,380		200,203,908
Parent: Did not meet cohort entry criteria	78,582,029	197,351	-199978288	225,620
Parent: Excluded due to insufficient enrollment	-27,693	169,658	-56919	168,701
Parent: Inclusion # 1.2.3	-7,584	162,074	-17110	151,591

Parent: Excluded based on Start of Prasgurel 10mg OR Ticagrelor 90mg	-139,539	22,535	-122209	29,382
Parent: Excluded based on Exclusion # 13 - PCI	-1,511	21,024	-1228	28,154
Parent: Excluded based on Enrollment with allowed gap	-16	21,008	-25	28,129
Parent: Final cohort		21,008		28,129
Did not meet cohort entry criteria	0	21,008	0	28,129
Excluded due to insufficient enrollment	0	21,008	0	28,129
Excluded due to prior use of referent	-325	20,683	-372	27,757
Excluded due to prior use of exposure	-341	20,342	-535	27,222
Excluded because patient qualified in >1 exposure category	-5	20,337	-3	27,219
Excluded based on Inclusion # 2 - Age \geq 18	0	20,337	0	27,219
Excluded based on Exclusion # 2 - history of stroke or TIA	-6,788	13,549	-6784	20,435
Excluded based on Exclusion # 3 - intracranial neoplasm, intracranial AVM, intracranial aneurysm	-15	13,534	-11	20,424
Excluded based on Exclusion # 4 - Active bleeding	-446	13,088	-595	19,829
Excluded based on Exclusion # 6 - Thrombocytopenia	-269	12,819	-261	19,568
Excluded based on Exclusion # 7 - Anemia	-1,033	11,786	-891	18,677
Excluded based on Exclusion # 10 - chronic renal insufficiency	-38	11,748	-37	18,640
Excluded based on Exclusion # 11 - Moderate/severe hepatic dysfunction	-544	11,204	-578	18,062
Excluded based on Exclusion # 12 - Increased risk of bradycardia events	-342	10,862	-413	17,649
Excluded based on Exclusion # 14 - CCI \geq 10	-24	10,838	-8	17,641
Excluded based on Exclusion # 15 - Concomitant therapy with strong CYP3A inhibitors/inducers	-28	10,810	-53	17,588
Excluded based on Exclusion # 19 - Pregnancy	-3	10,807	-6	17,582
Final cohort		10,807		17,582

prior 6 months.

6.2 Preliminary covariates:

- Age
- Sex

6. Variables

6.1 Exposure-related variables:

Study drug:

The study exposure of interest is initiation of ticagrelor. Initiation will be defined as starting treatment with ticagrelor or a comparator drug with no prior use of the corresponding drug in the past 6 months (washout period).

Comparator agents:

New initiators of prasugrel 10 mg, defined by no use of ticagrelor or prasugrel in the

- Combined Comorbidity Index (CCI), measured over the default baseline covariate assessment period, defined as 180 days prior to and including index date

Covariates listed above represent only a small subset of covariates that will ultimately be controlled for in the design and analysis. We use the covariates above only for initial feasibility analyses to judge whether there is likely to be sufficient overlap between treatment groups to proceed with the study. Remaining covariates are defined only after the study has passed the initial feasibility analysis and the initial power assessment and are listed in Table 1 (**Appendix B**).

6.3 Outcome variables and study follow-up:

6.3.1 Outcome variables

Primary effectiveness outcomes of interest (definitions provided in **Appendix A**):

- **Primary outcome:** composite of death, myocardial infarction, or stroke at 1 year after randomization
- Secondary outcomes:
 - Individual components:
 - Hospital admission for MI
 - Hospital admission for stroke
 - Death

Safety outcomes of interest:

1. Major bleeding

6.3.2 Study follow-up

Both as-treated (AT) and intention-to-treat (ITT) analyses will be conducted with treatment defined as the index drug on the day of cohort entry. Because adherence in the real-world databases is expected to be much worse than in the trial, the AT analysis is the **primary** analysis, as it targets the relative hazard of outcomes on treatment.

For the AT analyses, the follow-up will start the day after initiation of ticagrelor and comparator and will continue until the earliest date of the following events:

- The first occurrence of the outcome of interest, unless otherwise specified for selected outcomes,
- The date of end of continuous registration in the database,

- End of the study period,
- Measured death event occurs,
- Nursing home admission
 - Nursing home admissions are considered a censoring event because the data sources utilized typically provide little to no data on a patient, particularly on drug utilization, after admission. We will utilize this as an exclusion reason for cohorts for the same reason.
- The date of drug discontinuation, defined as the date of the last continuous treatment episode of the index drug (ticagrelor and comparator) plus a defined grace period (i.e., 30 days after the end of the last prescription's days' supply in main analyses).
- The date of augmentation or switching from exposure to comparator or vice versa
- The date of augmentation/switching from exposure or comparator to clopidogrel, measured as the initiation of clopidogrel starting from 1 day after cohort entry date
 - A dosage change on the index treatment does not fulfill this criterion
 - An added treatment that is not part of the exposure or comparator group does not fulfill this criterion

For the ITT analyses, the censoring based on the augmentation/switching and treatment discontinuation will be replaced with a maximum allowed follow-up time of 365 days.

7. Initial Feasibility Analysis

Aetion report links:

Optum: <https://bwh-dope.aetion.com/projects/details/1740/rwrs/71503>

Marketscan: <https://bwh-dope.aetion.com/projects/details/1739/rwrs/71505>

Date conducted: 06/11/2021

Complete Aetion feasibility analysis using age, sex, and CCI as the only covariates and the primary endpoint (Section 6.3.1) as the outcome. No measures of association will be computed nor will incidence rates stratified by treatment group.

- Report patient characteristics by treatment group

	Optum			Marketscan		
Variable	Exposure - Ticagrelor (90 mg)	Exposure - Prasugrel (10 mg)	Difference	Exposure - Ticagrelor (90 mg)	Exposure - Prasugrel (10 mg)	Difference
Number of patients	6,722	4,085	- (-, -)	9,025	8,557	- (-, -)
Age						
...mean (sd)	63.60 (11.12)	59.90 (10.02)	3.70 (3.29, 4.11)	58.41 (9.83)	56.88 (8.90)	1.54 (1.26, 1.81)
...median [IQR]	64.00 [56.00, 71.00]	60.00 [53.00, 67.00]	- (-, -)	59.00 [52.00, 63.00]	58.00 [51.00, 63.00]	- (-, -)
Gender						
...1 - Male; n (%)	4,796 (71.3%)	3,152 (77.2%)	-5.8% (- 7.5%, - 4.1%)	6,790 (75.2%)	6,835 (79.9%)	-4.6% (- 5.9%, - 3.4%)
...2 - Female; n (%)	1,925 (28.6%)	933 (22.8%)	5.8% (4.1%, 7.5%)	2,235 (24.8%)	1,722 (20.1%)	4.6% (3.4%, 5.9%)
CCI (180 days)- ICD9 and ICD10						
...mean (sd)	1.51 (1.96)	0.93 (1.74)	0.58 (0.51, 0.65)	0.74 (1.54)	0.50 (1.43)	0.24 (0.19, 0.28)
...median [IQR]	1.00 [0.00, 3.00]	1.00 [0.00, 2.00]	- (-, -)	0.00 [0.00, 2.00]	0.00 [-1.00, 1.00]	- (-, -)

- Report summary parameters of study population

FEASIBILITY- FOR STUDY OUTCOME		
	Optum	Marketscan
Variable	Value	Value
Number of patients in full cohort	10,807	17,582
Number of patients dropped as incomplete cases	0	0
Number of patients that did not begin follow-up	3	5

Effectiveness research with Real World Data to support FDA's regulatory decision making

Number of patients in analytic cohort	10,804	17,577
Number of events	777	1063
Number of person-years	7,415.55	13,945.70
Number of patients in group: Exposure - Ticagrelor (90 mg)	6,719	9,021
Number of patients in group: Exposure - Prasugrel (10 mg)	4,085	8,556
Risk per 1,000 patients	71.92	60.48
Rate per 1,000 person-years	104.78	76.22

- Report median follow-up time by treatment group

MEDIAN FOLLOW-UP TIME FOR STUDY OUTCOME		
Median Follow-Up Time (Days) [IQR]		
	Optum	Marketscan
Patient Group	Median Follow-Up Time (Days) [IQR]	Median Follow-Up Time (Days) [IQR]
Overall Patient Population	196 [58, 391]	249 [91, 420]
Referent	172 [58, 386]	230 [85, 412]
Exposure	232 [81, 403]	273 [109, 433]

- Report reasons for censoring in the overall study population

CENSORING REASONS FOR STUDY OUTCOME		
	Optum	Marketscan
Overall		
Outcome	368 (3.4%)	516 (2.9%)

Death	0 (0.0%)	0 (0.0%)
Start of an additional exposure	179 (1.7%)	331 (1.9%)
End of index exposure	4,994 (46.2%)	8,242 (46.9%)
Specified date reached	412 (3.8%)	734 (4.2%)
End of patient data	0 (0.0%)	0 (0.0%)
End of patient enrollment	1,873 (17.3%)	4,889 (27.8%)
Switch to clopidogrel + Nursing home admission	2,978 (27.6%)	2,865 (16.3%)

- Report overall risk of the primary outcome.

	Optum	Marketscan	Pooled
Risk per 1,000 patients	71.92	60.48	64.81

8. Initial Power Assessment

Action report links:

Optum: <https://bwh-dope.aetion.com/projects/details/1740/rwrs/71504>

Marketscan: <https://bwh-dope.aetion.com/projects/details/1739/rwrs/71508>

Date conducted: 06/11/2021

In order to complete the initial power analysis, the dummy outcome of a 90-day gap in database enrollment will be used. This outcome is used to ensure that no information on the comparative risks of the outcomes of interest are available at this stage. Complete a 1:1 PS-matched comparative analysis using this outcome. PS should include only 3 covariates: age, sex, and combined comorbidity index. Power calculations are based on the formulas from Chow et al. (2008).

- Stop analyses until feasibility and power are reviewed by primary investigators and FDA. Reviewers evaluate the results of the analyses described above in Sections 7 and 8, including numbers of patients, patient characteristics, follow-up time, and reasons for censoring by treatment group, as well as overall rates of outcomes and study power. These parameters are re-evaluated and reported in the subsequent sections, after incorporating feedback and refining the protocol.

Effectiveness research with Real World Data to support FDA's regulatory decision making

Pooled

Superiority Analysis	
Number of patients matched	24,266
Reference	12,133
Exposed	12,133
Risk per 1,000 patients	64.81
Desired HR from RCT	1.36
Alpha (2-sided)	0.05
Number of events expected	1572.67946
Power	0.999982406

Effectiveness research with Real World Data to support FDA's regulatory decision making

Marketscan

Superiority Analysis	
Number of patients matched	16,164
Reference	8,082
Exposed	8,082
Risk per 1,000 patients	60.48
Desired HR from RCT	1.36
Alpha (2-sided)	0.05
Number of events expected	977.59872
Power	0.997793559

Optum

Superiority Analysis	
Number of patients matched	8,102
Reference	4,051
Exposed	4,051
Risk per 1,000 patients	71.92
Desired HR from RCT	1.36
Alpha (2-sided)	0.05
Number of events expected	582.69584
Power	0.960047459

- Stop analyses until balance and final power assessment are reviewed by primary investigators, FDA, and assigned members of advisory board.

Reviewed by PI:		Date reviewed:	
Reviewed by FDA:		Date reviewed:	
Reasons for stopping analysis (if required):			

9. Balance Assessment

Action report name:

Optum: <https://bwh-dope.aetion.com/projects/details/1740/rwrs/71506>

Marketscan: <https://bwh-dope.aetion.com/projects/details/1739/rwrs/71510>

Date conducted: 06/10/2021

After review of initial feasibility and power analyses, complete creation of the remaining covariates from Section 6.2. Again, using the dummy outcome of a 90-day gap in database enrollment, complete a 1:1 PS-matched analysis. The PS should include the complete list of covariates.

- Provide plot of PS distributions stratified by treatment group.

Note- Please refer to **Appendix B**.

- Report covariate balance after matching.

Note- For Table 1, please refer to **Appendix B**.

- Report reasons for censoring by treatment group.

	Overall	Referent	Exposure
Dummy Outcome	0 (0.00%)	0 (0.00%)	0 (0.00%)
Death	45 (0.31%)	17 (0.23%)	28 (0.38%)
Start of an additional exposure	307 (2.10%)	248 (3.40%)	59 (0.81%)
End of index exposure	8,472 (58.03%)	4,309 (59.03%)	4,163 (57.03%)
Specified date reached	602 (4.12%)	245 (3.36%)	357 (4.89%)
End of patient enrollment	3,773 (25.84%)	1,714 (23.48%)	2,059 (28.21%)
Switch to clopidogrel + Nursing home admission	1,401 (9.60%)	767 (10.51%)	634 (8.68%)

- Report follow-up time by treatment group.

Median Follow-Up Time (Days) [IQR]		
Patient Group	Optum	Marketscan
Overall Patient Population	208 [58-395]	259 [99-430]
Referent	178 [58-391]	241 [88-419]

Exposure	229 [80-402]	286 [112-445]
----------	--------------	---------------

10. Final Power Assessment

Date conducted: 06/10/2021

- Re-calculate power in the appropriate excel table, using the revised number of matched patients from the PS-match in Section 9. All other parameters in the table should be the same as in Section 8.

Pooled

Superiority Analysis	
Number of patients matched	14,600
Reference	7,300
Exposed	7,300
Risk per 1,000 patients	65.52
Desired HR from RCT	1.36
Alpha (2-sided)	0.05
Number of events expected	956.592
Power	0.997405863

Marketscan

Effectiveness research with Real World Data to support FDA's regulatory decision making

Superiority Analysis	
Number of patients matched	9,604
Reference	4,802
Exposed	4,802
Risk per 1,000 patients	61.61
Desired HR from RCT	1.36
Alpha (2-sided)	0.05
Number of events expected	591.70244
Power	0.962446362

Optum

Superiority Analysis	
Number of patients matched	4,996
Reference	2,498
Exposed	2,498
Risk per 1,000 patients	71.92
Desired HR from RCT	1.36
Alpha (2-sided)	0.05
Number of events expected	359.31232
Power	0.830035796

- Stop analyses until balance and final power assessment are reviewed by primary investigators, FDA, and assigned members of advisory board.

Reviewed by PI:		Date reviewed:	
Reviewed by FDA:		Date reviewed:	
Reasons for stopping analysis (if required):			

11. Study Confidence and Concerns

Deadline for voting on study confidence and listing concerns:

Date votes and concerns are summarized:

- If final feasibility and power analyses are reviewed and approved, proceed to the remaining protocol steps.
- All study team and advisory board members that review this protocol should at this stage provide their level of confidence for the success of the RWD study in the [Google Form](#). This form also provides space for reviewers to list any concerns that they feel may

contribute to a failure to replicate the findings of the RCT, including differences in study populations, poor measurement of study variables, or residual confounding. All responses will be kept confidential and individual-level results will only be shared with the individual respondent.

- After the deadline for voting has passed, provide the distribution of responses and summarize all concerns here.

12. Register study protocol on clinicalTrials.gov

Date conducted:

- Register the study on [clinicalTrials.gov](https://clinicaltrials.gov) and upload this document.

13. Comparative Analyses

Action report name:

Date conducted:

13.1 For primary analysis:

13.2 For sensitivity analyses:

14. Requested Results

14.1 Table 1: Baseline characteristics before and after adjustment

Variable	Before adjustment			After adjustment		
	Referent	Exposure	Std. diff.	Referent	Exposure	Std. diff.
Number of patients			-			-
Age categories						
...						

14.2 Table 2: Follow-up time

Patient Group	Median Follow-Up Time (Days) [IQR]
Overall Patient Population	
Referent	
Exposure	

14.3 Table 3: Censoring events

	Overall	Referent	Exposure
Outcome			
Death			
Start of an additional exposure			
End of index exposure			
Specified date reached			
End of patient data			
End of patient enrollment			
...			

14.4 Table 4: Results from primary analyses;

Analysis	No. exposed events	No. referent events	Exposed rate	Referent rate	HR (95% CI)
Crude					
Analysis 1					
Analysis 2					
...					

HR, Hazard Ratio; CI, Confidence Interval.

14.5 Table 5: Results from secondary analyses;

15. References

Schupke S., Neumann F., Menichelli M., et al. Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes. N Engl J Med. 2019; 381:1524-1534

Chow S, Shao J, Wang H. 2008. *Sample Size Calculations in Clinical Research*. 2nd Ed. Chapman & Hall/CRC Biostatistics Series. page 177

Appendix A

Trial Name (with web links)

[ISAR-REACT 5](#)

Trial Name (with pdf links)

[ISAR-REACT 5](#)

NCT

[NCT01944800](#)

Therapeutic Area

Cardiology/Vascular Diseases

Study Batch

Antiplatelets

Brand Name

Brilinta

Generic Name

Ticagrelor

Sponsor

Deutsches Herzzentrum Muenchen

Year

2019

Measurable Endpoint

The primary end point was the composite of stroke, myocardial infarction, or death

Exposure

Ticagrelor

Comparator

Prasugrel

Population

Patients who were hospitalized for an acute coronary syndrome (ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction or unstable angina pectoris) with planned invasive strategy

Trial Finding

HR = 1.36 (95% CI, 1.09 to 1.70)

No. of Patients

4,018 (2,012 in exposed arm)

Power

80% power; 1895 patients in each group would be needed for the trial to detect a relative risk that was lower by 22.5% in the rate of the primary end point in the ticagrelor group as compared with the prasugrel group

Appendix A

Coronary angiography

Procedure codes any diagnosis position, inpatient and outpatient setting

Source : <https://www.cordis.com/content/dam/cordis/web/documents/fact-sheet/cordis-cardiology-reimbursement-fact-sheet.pdf>

CPT

93451 performed

Left heart catheterization including intraprocedural injection(s) for left ventriculography, imaging

93452 supervision and interpretation, when performed

Combined right and left heart catheterization including intraprocedural injection(s) for left ventriculography,

93453 imaging supervision and interpretation, when performed

93454 Coronary angiography

93455 Coronary angiography with bypass grafts

93456 Coronary angiography with right heart catheterization

93457 Coronary angiography and bypass grafts, with right heart catheterization

93458 Coronary angiography with left heart catheterization

93459 Coronary angiography and bypass grafts, with left heart catheterization

93460 Coronary angiography with right and left heart catheterization

93461 Coronary angiography with bypass grafts, right and left heart catheterization

93563 Injection/imaging for coronary angiography with cath for congenital anomaly

93564 Injection/imaging for bypass graft angiography with cath for congenital anomaly

93565 Injection/imaging for left heart angiography with cath for congenital anomaly

93566 Injection/imaging for right heart angiography with cath for congenital anomaly

Computed tomographic angiography, heart, coronary arteries and bypass grafts (when present), with

75574 contrast material, including 3D image postprocessing (including evaluation of cardiac structure and morphology, assessment of cardiac function, and evaluation of venous structures, if performed)

ICD-9 PX

37.21 Right heart cardiac catheterization

37.22 Left heart cardiac catheterization

37.23 Combined right and left heart cardiac catheterization

ICD 10 PX

Appendix A

B21	Fluoroscopy (heart)
B210xxx	Coronary Artery, Single
B211xxx	Coronary Arteries, Multiple
B212xxx	Coronary Artery Bypass Graft, Single
B213xxx	Coronary Artery Bypass Grafts, Multiple
B214xxx	Heart, Right
B215xxx	Heart, Left
B216xxx	Heart, Right and Left
B217xxx	Internal Mammary Bypass Graft, Right
B218xxx	Internal Mammary Bypass Graft, Left
B21Fxxx	Bypass Graft, Other
B22	CT Scan (heart)
B221xxx	Coronary Arteries, Multiple
B223xxx	Coronary Artery Bypass Grafts, Multiple
B226xxx	Heart, Right and Left
B31	Fluoroscopy (upper arteries)
B312xxx	Subclavian Artery, Left
B313xxx	Common Carotid Artery, Right
B314xxx	Common Carotid Artery, Left
B315xxx	Common Carotid Arteries, Bilateral
B316xxx	Internal Carotid Artery, Right
B317xxx	Internal Carotid Artery, Left
B318xxx	Internal Carotid Arteries, Bilateral
B319xxx	External Carotid Artery, Right
B31Bxxx	External Carotid Artery, Left
B31Cxxx	External Carotid Arteries, Bilateral
B32	CT scan (upper arteries)
B325xxx	Common Carotid Arteries, Bilateral
B328xxx	Internal Carotid Arteries, Bilateral

Appendix A

Major bleeding exclusion criteria: 1 inpatient (any position) or 2 outpatient diagnosis (separated by 7-365 days)

562.02	(ICD9) DIVERTICULOSIS OF SMALL INTESTINE WITH HEMORRHAGE
562.03	(ICD9) DIVERTICULITIS OF SMALL INTESTINE WITH HEMORRHAGE
562.12	(ICD9) DIVERTICULOSIS OF COLON WITH HEMORRHAGE
562.13	(ICD9) DIVERTICULITIS OF COLON WITH HEMORRHAGE
568.81	(ICD9) HEMOPERITONEUM (NONTRAUMATIC)
569.3	(ICD9) HEMORRHAGE OF RECTUM AND ANUS
569.83	(ICD9) PERFORATION OF INTESTINE
569.85	(ICD9) ANGIODYSPLASIA OF INTESTINE WITH HEMORRHAGE
569.86	(ICD9) DIEULAFOY LESION (HEMORRHAGIC) OF INTESTINE
578	(ICD9) HEMATEMESIS
578.9	(ICD9) HEMORRHAGE OF GASTROINTESTINAL TRACT UNSPECIFIED
423	(ICD9) HEMOPERICARDIUM
432	(ICD9) NONTRAUMATIC EXTRADURAL HEMORRHAGE
432.1	(ICD9) SUBDURAL HEMORRHAGE
432.9	(ICD9) UNSPECIFIED INTRACRANIAL HEMORRHAGE
459	(ICD9) HEMORRHAGE UNSPECIFIED
531	(ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE
531	(ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
531.01	(ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE WITH OBSTRUCTION
531.2	(ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION
531.2	(ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
531.21	(ICD9) ACUTE GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
531.4	(ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE
531.4	(ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
531.41	(ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE WITH OBSTRUCTION
531.6	(ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION
531.6	(ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION

Appendix A

531.61	(ICD9) CHRONIC OR UNSPECIFIED GASTRIC ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
532	(ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE
532	(ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
532.01	(ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
532.2	(ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION
532.2	(ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
532.21	(ICD9) ACUTE DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
532.4	(ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE
532.4	(ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
532.41	(ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
532.6	(ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION
532.6	(ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
532.61	(ICD9) CHRONIC OR UNSPECIFIED DUODENAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
533	(ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE
533	(ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITHOUT OBSTRUCTION
533.01	(ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITH OBSTRUCTION
533.2	(ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION
533.2	(ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
533.21	(ICD9) ACUTE PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
533.4	(ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE
533.4	(ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITHOUT OBSTRUCTION
533.41	(ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE WITH OBSTRUCTION

Appendix A

533.6	(ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION
533.6	(ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
533.61	(ICD9) CHRONIC OR UNSPECIFIED PEPTIC ULCER OF UNSPECIFIED SITE WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
534	(ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE
534	(ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
534.01	(ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
534.2	(ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION
534.2	(ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
534.21	(ICD9) ACUTE GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
534.4	(ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE
534.4	(ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE WITHOUT OBSTRUCTION
534.41	(ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE WITH OBSTRUCTION
534.6	(ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION
534.6	(ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITHOUT OBSTRUCTION
534.61	(ICD9) CHRONIC OR UNSPECIFIED GASTROJEJUNAL ULCER WITH HEMORRHAGE AND PERFORATION WITH OBSTRUCTION
578.1	(ICD9) BLOOD IN STOOL
719.1	(ICD9) HEMARTHROSIS
719.1	(ICD9) HEMARTHROSIS SITE UNSPECIFIED
719.11	(ICD9) HERARTHROSIS INVOLVING SHOULDER REGION
719.12	(ICD9) HEMARTHORSIS INVOLVING UPPER ARM
719.13	(ICD9) HEMARTHROSIS INVOLVING FOREARM

Appendix A

719.14	(ICD9) HEMARTHROSIS INVOLVING HAND
719.15	(ICD9) HEMARTHROSIS INVOLVING PELVIC REGION AND THIGH
719.16	(ICD9) HEMARTHROSIS INVOLVING LOWER LEG
719.17	(ICD9) HEMARTHROSIS INVOLVING ANKLE AND FOOT
719.18	(ICD9) HEMARTHROSIS INVOLVING OTHER SPECIFIED SITES
719.19	(ICD9) HEMARTHROSIS INVOLVING MULTIPLE SITES
430	(ICD9) SUBARACHNOID HEMORRHAGE
431	(ICD9) INTRACEREBRAL HEMORRHAGE
I31.2	(ICD10) Hemopericardium, not elsewhere classified
I60.00	(ICD10) Nontraumatic subarachnoid hemorrhage from unspecified carotid siphon and bifurcation
I60.01	(ICD10) Nontraumatic subarachnoid hemorrhage from right carotid siphon and bifurcation
I60.02	(ICD10) Nontraumatic subarachnoid hemorrhage from left carotid siphon and bifurcation
I60.10	(ICD10) Nontraumatic subarachnoid hemorrhage from unspecified middle cerebral artery
I60.11	(ICD10) Nontraumatic subarachnoid hemorrhage from right middle cerebral artery
I60.12	(ICD10) Nontraumatic subarachnoid hemorrhage from left middle cerebral artery
I60.2	(ICD10) Nontraumatic subarachnoid hemorrhage from anterior communicating artery
I60.30	(ICD10) Nontraumatic subarachnoid hemorrhage from unspecified posterior communicating artery
I60.31	(ICD10) Nontraumatic subarachnoid hemorrhage from right posterior communicating artery
I60.32	(ICD10) Nontraumatic subarachnoid hemorrhage from left posterior communicating artery
I60.4	(ICD10) Nontraumatic subarachnoid hemorrhage from basilar artery
I60.50	(ICD10) Nontraumatic subarachnoid hemorrhage from unspecified vertebral artery
I60.51	(ICD10) Nontraumatic subarachnoid hemorrhage from right vertebral artery
I60.52	(ICD10) Nontraumatic subarachnoid hemorrhage from left vertebral artery
I60.6	(ICD10) Nontraumatic subarachnoid hemorrhage from other intracranial arteries
I60.7	(ICD10) Nontraumatic subarachnoid hemorrhage from unspecified intracranial artery
I60.8	(ICD10) Other nontraumatic subarachnoid hemorrhage
I60.9	(ICD10) Nontraumatic subarachnoid hemorrhage, unspecified
I61.0	(ICD10) Nontraumatic intracerebral hemorrhage in hemisphere, subcortical
I61.1	(ICD10) Nontraumatic intracerebral hemorrhage in hemisphere, cortical
I61.2	(ICD10) Nontraumatic intracerebral hemorrhage in hemisphere, unspecified
I61.3	(ICD10) Nontraumatic intracerebral hemorrhage in brain stem

Appendix A

I61.4	(ICD10) Nontraumatic intracerebral hemorrhage in cerebellum
I61.5	(ICD10) Nontraumatic intracerebral hemorrhage, intraventricular
I61.6	(ICD10) Nontraumatic intracerebral hemorrhage, multiple localized
I61.8	(ICD10) Other nontraumatic intracerebral hemorrhage
I61.9	(ICD10) Nontraumatic intracerebral hemorrhage, unspecified
I62.00	(ICD10) Nontraumatic subdural hemorrhage, unspecified
I62.01	(ICD10) Nontraumatic acute subdural hemorrhage
I62.02	(ICD10) Nontraumatic subacute subdural hemorrhage
I62.03	(ICD10) Nontraumatic chronic subdural hemorrhage
I62.1	(ICD10) Nontraumatic extradural hemorrhage
I62.9	(ICD10) Nontraumatic intracranial hemorrhage, unspecified
K25.0	(ICD10) Acute gastric ulcer with hemorrhage
K25.2	(ICD10) Acute gastric ulcer with both hemorrhage and perforation
K25.4	(ICD10) Chronic or unspecified gastric ulcer with hemorrhage
K25.6	(ICD10) Chronic or unspecified gastric ulcer with both hemorrhage and perforation
K26.0	(ICD10) Acute duodenal ulcer with hemorrhage
K26.2	(ICD10) Acute duodenal ulcer with both hemorrhage and perforation
K26.4	(ICD10) Chronic or unspecified duodenal ulcer with hemorrhage
K26.6	(ICD10) Chronic or unspecified duodenal ulcer with both hemorrhage and perforation
K27.0	(ICD10) Acute peptic ulcer, site unspecified, with hemorrhage
K27.2	(ICD10) Acute peptic ulcer, site unspecified, with both hemorrhage and perforation
K27.4	(ICD10) Chronic or unspecified peptic ulcer, site unspecified, with hemorrhage
K27.6	(ICD10) Chronic or unspecified peptic ulcer, site unspecified, with both hemorrhage and perforation
K28.0	(ICD10) Acute gastrojejunal ulcer with hemorrhage
K28.2	(ICD10) Acute gastrojejunal ulcer with both hemorrhage and perforation
K28.4	(ICD10) Chronic or unspecified gastrojejunal ulcer with hemorrhage
K28.6	(ICD10) Chronic or unspecified gastrojejunal ulcer with both hemorrhage and perforation
K55.21	(ICD10) Angiodysplasia of colon with hemorrhage
K56.60	(ICD10) Unspecified intestinal obstruction
K57.01	(ICD10) Diverticulitis of small intestine with perforation and abscess with bleeding
K57.11	(ICD10) Diverticulosis of small intestine without perforation or abscess with bleeding

Appendix A

K57.13	(ICD10) Diverticulitis of small intestine without perforation or abscess with bleeding
K57.21	(ICD10) Diverticulitis of large intestine with perforation and abscess with bleeding
K57.31	(ICD10) Diverticulosis of large intestine without perforation or abscess with bleeding
K57.33	(ICD10) Diverticulitis of large intestine without perforation or abscess with bleeding
K57.41	(ICD10) Diverticulitis of both small and large intestine with perforation and abscess with bleeding
K57.51	(ICD10) Diverticulosis of both small and large intestine without perforation or abscess with bleeding
K57.53	(ICD10) Diverticulitis of both small and large intestine without perforation or abscess with bleeding
K57.81	(ICD10) Diverticulitis of intestine, part unspecified, with perforation and abscess with bleeding
K57.91	(ICD10) Diverticulosis of intestine, part unspecified, without perforation or abscess with bleeding
K57.93	(ICD10) Diverticulitis of intestine, part unspecified, without perforation or abscess with bleeding
K62.5	(ICD10) Hemorrhage of anus and rectum
K63.1	(ICD10) Perforation of intestine (nontraumatic)
K63.81	(ICD10) Dieulafoy lesion of intestine
K66.1	(ICD10) Hemoperitoneum
K92.0	(ICD10) Hematemesis
K92.1	(ICD10) Melena
K92.2	(ICD10) Gastrointestinal hemorrhage, unspecified
M25.00	(ICD10) Hemarthrosis, unspecified joint
M25.011	(ICD10) Hemarthrosis, right shoulder
M25.012	(ICD10) Hemarthrosis, left shoulder
M25.019	(ICD10) Hemarthrosis, unspecified shoulder
M25.021	(ICD10) Hemarthrosis, right elbow
M25.022	(ICD10) Hemarthrosis, left elbow
M25.029	(ICD10) Hemarthrosis, unspecified elbow
M25.031	(ICD10) Hemarthrosis, right wrist
M25.032	(ICD10) Hemarthrosis, left wrist
M25.039	(ICD10) Hemarthrosis, unspecified wrist
M25.041	(ICD10) Hemarthrosis, right hand
M25.042	(ICD10) Hemarthrosis, left hand
M25.049	(ICD10) Hemarthrosis, unspecified hand

Appendix A

M25.051	(ICD10) Hemarthrosis, right hip
M25.052	(ICD10) Hemarthrosis, left hip
M25.059	(ICD10) Hemarthrosis, unspecified hip
M25.061	(ICD10) Hemarthrosis, right knee
M25.062	(ICD10) Hemarthrosis, left knee
M25.069	(ICD10) Hemarthrosis, unspecified knee
M25.071	(ICD10) Hemarthrosis, right ankle
M25.072	(ICD10) Hemarthrosis, left ankle
M25.073	(ICD10) Hemarthrosis, unspecified ankle
M25.074	(ICD10) Hemarthrosis, right foot
M25.075	(ICD10) Hemarthrosis, left foot
M25.076	(ICD10) Hemarthrosis, unspecified foot
M25.08	(ICD10) Hemarthrosis, other specified site
R58	(ICD10) Hemorrhage, not elsewhere classified
R04	(ICD10) Hemorrhage from respiratory passages
R04.0	(ICD10) Epistaxis
R04.1	(ICD10) Hemorrhage from throat
R04.2	(ICD10) Hemoptysis
R04.8	(ICD10) Hemorrhage from other sites in respiratory passages
R04.81	(ICD10) Acute idiopathic pulmonary hemorrhage in infants
R04.89	(ICD10) Hemorrhage from other sites in respiratory passages
R04.9	(ICD10) Hemorrhage from respiratory passages, unspecified
R31	(ICD10) Hematuria
R31.0	(ICD10) Gross hematuria
R31.1	(ICD10) Benign essential microscopic hematuria
R31.2	(ICD10) Other microscopic hematuria
R31.21	
R31.29	
R31.9	(ICD10) Hematuria, unspecified
784.7	(ICD9) EPISTAXIS
784.8	(ICD9) HEMORRHAGE FROM THROAT

Appendix A

599.7	(ICD9) HEMATURIA
599.7	(ICD9) HEMATURIA UNSPECIFIED
599.71	(ICD9) GROSS HEMATURIA
599.72	(ICD9) MICROSCOPIC HEMATURIA
786.3	(ICD9) HEMOPTYSIS
786.3	(ICD9) HEMOPTYSIS UNSPECIFIED
786.31	(ICD9) ACUTE IDIOPATHIC PULMONARY HEMORRHAGE IN INFANTS
786.39	(ICD9) OTHER HEMOPTYSIS

The occurrence of Inpatient with the following attributes:

Legacy Attribute Procedure Code (Any Position) is any of: { "44.43", "43255", "0W3P8ZZ" }

44.43	(ICD9) ENDOSCOPIC CONTROL OF GASTRIC OR DUODENAL BLEEDING
43255	(HCPCS) Esophagogastroduodenoscopy, flexible, transoral; with control of bleeding, any method / Upper gastrointestinal endoscopy including esophagus, stomach, and either the duodenum and/or jejunum as appropriate; with control of bleeding, any method
0W3P8ZZ	(ICD10) Control Bleeding in Gastrointestinal Tract, Via Natural or Artificial Opening Endoscopic

Appendix A

PCI

Procedure codes in any position, inpatient or outpatient setting

HCP/PCS/CPT codes:

	(HCP/PCS) Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)
92925	
	(HCP/PCS) Percutaneous transluminal coronary angioplasty; single major coronary artery or branch
92920	
	(HCP/PCS) Percutaneous transluminal coronary angioplasty; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)
92921	
	(HCP/PCS) Percutaneous transluminal coronary atherectomy, with coronary angioplasty when performed; single major coronary artery or branch
92924	
	(HCP/PCS) Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)
92929	
	(HCP/PCS) Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch
92933	
	(HCP/PCS) Percutaneous transluminal coronary atherectomy, with intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (List separately in addition to code for primary procedure)
92934	
	(HCP/PCS) Percutaneous transcatheter placement of intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch
92928	

ICD-9 px codes:

0.66	(ICD9) PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY [PTCA]
36.09	(ICD9) OTHER REMOVAL OF CORONARY ARTERY OBSTRUCTION
36.06	(ICD9) INSERTION OF NON
36.07	(ICD9) INSERTION OF DRUG

ICD-10 px codes:

027004Z	(ICD10) Dilation of Coronary Artery, One Artery with Drug
---------	---

Appendix A

027005Z	(ICD10) Dilation of Coronary Artery, One Artery with Two Drug
02700GZ	(ICD10) Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, Open Approach
027035Z	(ICD10) Dilation of Coronary Artery, One Artery with Two Drug
027037Z	(ICD10) Dilation of Coronary Artery, One Artery with Four or More Drug
02703EZ	(ICD10) Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Percutaneous Approach
02703FZ	(ICD10) Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Percutaneous Approach
270456	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug
027045Z	(ICD10) Dilation of Coronary Artery, One Artery with Two Drug
027046Z	(ICD10) Dilation of Coronary Artery, One Artery with Three Drug
02704DZ	(ICD10) Dilation of Coronary Artery, One Artery with Intraluminal Device, Percutaneous Endoscopic Approach
2.70E+09	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach
02704G6	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach
02704TZ	(ICD10) Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach
027104Z	(ICD10) Dilation of Coronary Artery, Two Arteries with Drug
027105Z	(ICD10) Dilation of Coronary Artery, Two Arteries with Two Drug
271066	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug
02710GZ	(ICD10) Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, Open Approach
271466	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug
02714FZ	(ICD10) Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Percutaneous Endoscopic Approach
02714Z6	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, Percutaneous Endoscopic Approach
027205Z	(ICD10) Dilation of Coronary Artery, Three Arteries with Two Drug

Appendix A

272346	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug
027235Z	(ICD10) Dilation of Coronary Artery, Three Arteries with Two Drug
272366	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug
	(ICD10) Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices,
02723EZ	Percutaneous Approach
272446	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug
027244Z	(ICD10) Dilation of Coronary Artery, Three Arteries with Drug
272476	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug
	(ICD10) Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices,
02724FZ	Percutaneous Endoscopic Approach
	(ICD10) Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Open
02730DZ	Approach
	(ICD10) Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices,
02730FZ	Open Approach
	(ICD10) Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal
02730TZ	Device, Open Approach
273346	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug
	(ICD10) Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices,
02733FZ	Percutaneous Approach
	(ICD10) Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal
02733TZ	Device, Percutaneous Approach
273446	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug
	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More
273476	Drug
	(ICD10) Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices,
02734EZ	Percutaneous Endoscopic Approach
	(ICD10) Extirpation of Matter from Coronary Artery, One Artery, Bifurcation, Percutaneous
02C04Z6	Endoscopic Approach
	(ICD10) Extirpation of Matter from Coronary Artery, One Artery, Percutaneous Endoscopic
02C04ZZ	Approach

Appendix A

02C23ZZ	(ICD10) Extirpation of Matter from Coronary Artery, Three Arteries, Percutaneous Approach
02C24Z6	(ICD10) Extirpation of Matter from Coronary Artery, Three Arteries, Bifurcation, Percutaneous Endoscopic Approach
02C33Z6	(ICD10) Extirpation of Matter from Coronary Artery, Four or More Arteries, Bifurcation, Percutaneous Approach
02C33ZZ	(ICD10) Extirpation of Matter from Coronary Artery, Four or More Arteries, Percutaneous Approach
02700G6	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal Devices, Open Approach
02700TZ	(ICD10) Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, Open Approach
270346	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Drug
027034Z	(ICD10) Dilation of Coronary Artery, One Artery with Drug
270356	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug
02703D6	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, Percutaneous Approach
02703TZ	(ICD10) Dilation of Coronary Artery, One Artery with Radioactive Intraluminal Device, Percutaneous Approach
027044Z	(ICD10) Dilation of Coronary Artery, One Artery with Drug
02704D6	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach
2.71E+09	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal Devices, Open Approach
02710EZ	(ICD10) Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Open Approach
02710FZ	(ICD10) Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Open Approach
027134Z	(ICD10) Dilation of Coronary Artery, Two Arteries with Drug
02713D6	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device, Percutaneous Approach

Appendix A

02713EZ	(ICD10) Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Percutaneous Approach
02713TZ	(ICD10) Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device, Percutaneous Approach
02713ZZ	(ICD10) Dilation of Coronary Artery, Two Arteries, Percutaneous Approach
027147Z	(ICD10) Dilation of Coronary Artery, Two Arteries with Four or More Drug
02714GZ	(ICD10) Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach
027204Z	(ICD10) Dilation of Coronary Artery, Three Arteries with Drug
272056	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug
02720FZ	(ICD10) Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, Open Approach
02720TZ	(ICD10) Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device, Open Approach
027237Z	(ICD10) Dilation of Coronary Artery, Three Arteries with Four or More Drug
02723FZ	(ICD10) Dilation of Coronary Artery, Three Arteries with Three Intraluminal Devices, Percutaneous Approach
027245Z	(ICD10) Dilation of Coronary Artery, Three Arteries with Two Drug
272466	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug
027246Z	(ICD10) Dilation of Coronary Artery, Three Arteries with Three Drug
02724Z6	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, Percutaneous Endoscopic Approach
273046	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Drug
273076	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Drug
273366	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug
027337Z	(ICD10) Dilation of Coronary Artery, Four or More Arteries with Four or More Drug
02733T6	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach
02733Z6	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, Percutaneous Approach

Appendix A

027344Z	(ICD10) Dilation of Coronary Artery, Four or More Arteries with Drug
027346Z	(ICD10) Dilation of Coronary Artery, Four or More Arteries with Three Drug
02734D6	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach
02734DZ	(ICD10) Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Percutaneous Endoscopic Approach
02734F6	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach
02734TZ	(ICD10) Dilation of Coronary Artery, Four or More Arteries with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach
02C03Z6	(ICD10) Extirpation of Matter from Coronary Artery, One Artery, Bifurcation, Percutaneous Approach
270066	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug
027007Z	(ICD10) Dilation of Coronary Artery, One Artery with Four or More Drug
02700D6	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Intraluminal Device, Open Approach
02700DZ	(ICD10) Dilation of Coronary Artery, One Artery with Intraluminal Device, Open Approach
2.70E+09	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices, Open Approach
02700EZ	(ICD10) Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Open Approach
02700F6	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal Devices, Open Approach
02700FZ	(ICD10) Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Open Approach
027036Z	(ICD10) Dilation of Coronary Artery, One Artery with Three Drug
2.70E+09	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach
270466	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug
270476	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug

Appendix A

02704EZ	(ICD10) Dilation of Coronary Artery, One Artery with Two Intraluminal Devices, Percutaneous Endoscopic Approach
02704FZ	(ICD10) Dilation of Coronary Artery, One Artery with Three Intraluminal Devices, Percutaneous Endoscopic Approach
271046	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug
271076	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug
02710F6	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal Devices, Open Approach
02710T6	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive Intraluminal Device, Open Approach
271356	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug
027135Z	(ICD10) Dilation of Coronary Artery, Two Arteries with Two Drug
02713Z6	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, Percutaneous Approach
271456	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug
02714D6	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach
02714F6	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach
02714T6	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach
027206Z	(ICD10) Dilation of Coronary Artery, Three Arteries with Three Drug
027207Z	(ICD10) Dilation of Coronary Artery, Three Arteries with Four or More Drug
02720DZ	(ICD10) Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Open Approach
2.72E+09	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal Devices, Open Approach
02720EZ	(ICD10) Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, Open Approach
02720GZ	(ICD10) Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices, Open Approach

Appendix A

02720T6	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive Intraluminal Device, Open Approach
027234Z	(ICD10) Dilation of Coronary Artery, Three Arteries with Drug
02723D6	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device, Percutaneous Approach
02723DZ	(ICD10) Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Percutaneous Approach
027247Z	(ICD10) Dilation of Coronary Artery, Three Arteries with Four or More Drug
02724F6	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach
02724T6	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach
02724TZ	(ICD10) Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach
02724ZZ	(ICD10) Dilation of Coronary Artery, Three Arteries, Percutaneous Endoscopic Approach
273056	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug
273066	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug
02730D6	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal Device, Open Approach
02730T6	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive Intraluminal Device, Open Approach
273356	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug
02733DZ	(ICD10) Dilation of Coronary Artery, Four or More Arteries with Intraluminal Device, Percutaneous Approach
2.73E+09	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach
027345Z	(ICD10) Dilation of Coronary Artery, Four or More Arteries with Two Drug
02734GZ	(ICD10) Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach
02734ZZ	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Percutaneous Endoscopic Approach

Appendix A

02C14ZZ	(ICD10) Extirpation of Matter from Coronary Artery, Two Arteries, Percutaneous Endoscopic Approach
02700T6	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal Device, Open Approach
270366	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Three Drug
270376	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug
02703DZ	(ICD10) Dilation of Coronary Artery, One Artery with Intraluminal Device, Percutaneous Approach
02703GZ	(ICD10) Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, Percutaneous Approach
02703Z6	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, Percutaneous Approach
02703ZZ	(ICD10) Dilation of Coronary Artery, One Artery, Percutaneous Approach
270446	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Drug
02704GZ	(ICD10) Dilation of Coronary Artery, One Artery with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach
02704T6	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach
02704ZZ	(ICD10) Dilation of Coronary Artery, One Artery, Percutaneous Endoscopic Approach
027107Z	(ICD10) Dilation of Coronary Artery, Two Arteries with Four or More Drug
02710DZ	(ICD10) Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Open Approach
02710TZ	(ICD10) Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device, Open Approach
271346	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug
271376	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug
027137Z	(ICD10) Dilation of Coronary Artery, Two Arteries with Four or More Drug
2.71E+09	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach
271446	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Drug
027146Z	(ICD10) Dilation of Coronary Artery, Two Arteries with Three Drug

Appendix A

02714DZ	(ICD10) Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Percutaneous Endoscopic Approach
02714G6	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach
02714TZ	(ICD10) Dilation of Coronary Artery, Two Arteries with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach
272046	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Drug
272066	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Drug
02720D6	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device, Open Approach
02720G6	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Intraluminal Devices, Open Approach
027236Z	(ICD10) Dilation of Coronary Artery, Three Arteries with Three Drug
02723GZ	(ICD10) Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices, Percutaneous Approach
02723TZ	(ICD10) Dilation of Coronary Artery, Three Arteries with Radioactive Intraluminal Device, Percutaneous Approach
02723Z6	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, Percutaneous Approach
02724D6	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Intraluminal Device, Percutaneous Endoscopic Approach
2.72E+09	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach
02724GZ	(ICD10) Dilation of Coronary Artery, Three Arteries with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach
027306Z	(ICD10) Dilation of Coronary Artery, Four or More Arteries with Three Drug
027307Z	(ICD10) Dilation of Coronary Artery, Four or More Arteries with Four or More Drug
02730EZ	(ICD10) Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices, Open Approach
02730F6	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Intraluminal Devices, Open Approach

Appendix A

02730G6	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Intraluminal Devices, Open Approach
027334Z	(ICD10) Dilation of Coronary Artery, Four or More Arteries with Drug
027335Z	(ICD10) Dilation of Coronary Artery, Four or More Arteries with Two Drug
273376	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Drug
02733EZ	(ICD10) Dilation of Coronary Artery, Four or More Arteries with Two Intraluminal Devices, Percutaneous Approach
02733F6	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach
273456	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Drug
2.73E+09	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach
02C23Z6	(ICD10) Extirpation of Matter from Coronary Artery, Three Arteries, Bifurcation, Percutaneous Approach
270046	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Drug
270056	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Two Drug
027006Z	(ICD10) Dilation of Coronary Artery, One Artery with Three Drug
270076	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Drug
02703F6	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach
02703G6	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach
02703T6	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach
027047Z	(ICD10) Dilation of Coronary Artery, One Artery with Four or More Drug
02704F6	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, with Three Intraluminal Devices, Percutaneous Endoscopic Approach
02704Z6	(ICD10) Dilation of Coronary Artery, One Artery, Bifurcation, Percutaneous Endoscopic Approach
271056	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Drug

Appendix A

027106Z	(ICD10) Dilation of Coronary Artery, Two Arteries with Three Drug
02710D6	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Intraluminal Device, Open Approach
02710G6	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Intraluminal Devices, Open Approach
271366	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Drug
027136Z	(ICD10) Dilation of Coronary Artery, Two Arteries with Three Drug
02713DZ	(ICD10) Dilation of Coronary Artery, Two Arteries with Intraluminal Device, Percutaneous Approach
02713F6	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach
02713FZ	(ICD10) Dilation of Coronary Artery, Two Arteries with Three Intraluminal Devices, Percutaneous Approach
02713G6	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach
02713GZ	(ICD10) Dilation of Coronary Artery, Two Arteries with Four or More Intraluminal Devices, Percutaneous Approach
02713T6	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach
027144Z	(ICD10) Dilation of Coronary Artery, Two Arteries with Drug
027145Z	(ICD10) Dilation of Coronary Artery, Two Arteries with Two Drug
271476	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Four or More Drug
2.71E+09	(ICD10) Dilation of Coronary Artery, Two Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Endoscopic Approach
02714EZ	(ICD10) Dilation of Coronary Artery, Two Arteries with Two Intraluminal Devices, Percutaneous Endoscopic Approach
02714ZZ	(ICD10) Dilation of Coronary Artery, Two Arteries, Percutaneous Endoscopic Approach
272076	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug
02720F6	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal Devices, Open Approach
272356	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug

Appendix A

272376	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Drug
2.72E+09	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Intraluminal Devices, Percutaneous Approach
02723F6	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Three Intraluminal Devices, Percutaneous Approach
02723G6	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach
02723T6	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Approach
02723ZZ	(ICD10) Dilation of Coronary Artery, Three Arteries, Percutaneous Approach
272456	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Two Drug
02724DZ	(ICD10) Dilation of Coronary Artery, Three Arteries with Intraluminal Device, Percutaneous Endoscopic Approach
02724EZ	(ICD10) Dilation of Coronary Artery, Three Arteries with Two Intraluminal Devices, Percutaneous Endoscopic Approach
02724G6	(ICD10) Dilation of Coronary Artery, Three Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach
027304Z	(ICD10) Dilation of Coronary Artery, Four or More Arteries with Drug
027305Z	(ICD10) Dilation of Coronary Artery, Four or More Arteries with Two Drug
2.73E+09	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Two Intraluminal Devices, Open Approach
02730GZ	(ICD10) Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal Devices, Open Approach
027336Z	(ICD10) Dilation of Coronary Artery, Four or More Arteries with Three Drug
02733D6	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Intraluminal Device, Percutaneous Approach
02733G6	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Approach
02733GZ	(ICD10) Dilation of Coronary Artery, Four or More Arteries with Four or More Intraluminal Devices, Percutaneous Approach
02733ZZ	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Percutaneous Approach

Appendix A

273466	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Three Drug
027347Z	(ICD10) Dilation of Coronary Artery, Four or More Arteries with Four or More Drug
02734FZ	(ICD10) Dilation of Coronary Artery, Four or More Arteries with Three Intraluminal Devices, Percutaneous Endoscopic Approach
02734G6	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Four or More Intraluminal Devices, Percutaneous Endoscopic Approach
02734T6	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, with Radioactive Intraluminal Device, Percutaneous Endoscopic Approach
02734Z6	(ICD10) Dilation of Coronary Artery, Four or More Arteries, Bifurcation, Percutaneous Endoscopic Approach
02C03ZZ	(ICD10) Extirpation of Matter from Coronary Artery, One Artery, Percutaneous Approach
02C13Z6	(ICD10) Extirpation of Matter from Coronary Artery, Two Arteries, Bifurcation, Percutaneous Approach
02C13ZZ	(ICD10) Extirpation of Matter from Coronary Artery, Two Arteries, Percutaneous Approach
02C14Z6	(ICD10) Extirpation of Matter from Coronary Artery, Two Arteries, Bifurcation, Percutaneous Endoscopic Approach
02C24ZZ	(ICD10) Extirpation of Matter from Coronary Artery, Three Arteries, Percutaneous Endoscopic Approach
02C34Z6	(ICD10) Extirpation of Matter from Coronary Artery, Four or More Arteries, Bifurcation, Percutaneous Endoscopic Approach
02C34ZZ	(ICD10) Extirpation of Matter from Coronary Artery, Four or More Arteries, Percutaneous Endoscopic Approach

Appendix A

Title

Pregnancy

ICD-9 Dx inpatient any position

650	Normal delivery
660	Obstructed labor
661	Abnormality of forces of labor
662	Long labor
663	Umbilical cord complications during labor and delivery
664	Trauma to perineum and vulva during delivery
665	Other obstetrical trauma
667	Retained placenta or membranes without hemorrhage
668	Complications of the administration of anesthetic or other sedation in labor and delivery
669.94	Unspecified complication of labor and delivery postpartum condition or complication
V24	Postpartum care and examination
V24.0	Postpartum care and examination immediately after delivery
V24.1	Postpartum care and examination of lactating mother
V24.2	Routine postpartum follow
V27	Outcome of delivery
V27.0	Mother with single liveborn
V27.1	Mother with single stillborn
V27.2	Mother with twins both liveborn
V27.3	Mother with twins one liveborn and one stillborn
V27.4	Mother with twins both stillborn
V27.5	Mother with other multiple birth all liveborn
V27.6	Mother with other multiple birth some liveborn
V27.7	Mother with other multiple birth all stillborn
V27.9	Mother with unspecified outcome of delivery

Appendix A

ICD-9 Px inpatient any position

72.0	Low forceps operation
72.1	Low forceps operation with episiotomy
72.2	Mid forceps operation
72.21	Mid forceps operation with episiotomy
72.29	Other mid forceps operation
72.3	High forceps operation
72.31	High forceps operation with episiotomy
72.39	Other high forceps operation
72.4	Forceps rotation of fetal head
72.5	Breech extraction
72.51	Partial breech extraction with forceps to aftercoming head
72.52	Other partial breech extraction
72.53	Total breech extraction with forceps to aftercoming head
72.54	Other total breech extraction
72.6	Forceps application to aftercoming head
72.7	Vacuum extraction
72.71	Vacuum extraction with episiotomy
72.79	Other vacuum extraction
72.8	Other specified instrumental delivery
72.9	Unspecified instrumental delivery
73.0	Artificial rupture of membranes
73.01	Induction of labor by artificial rupture of membranes
73.09	Other artificial rupture of membranes
73.1	Other surgical induction of labor
73.2	Internal and combined version and extraction
73.21	Internal and combined version without extraction
73.22	Internal and combined version with extraction
73.3	Failed forceps
73.4	Medical induction of labor
73.5	Manually assisted delivery

Appendix A

73.51	Manual rotation of fetal head
73.59	Other manually assisted delivery
73.6	Episiotomy
73.8	Operations on fetus to facilitate delivery
73.9	Other operations assisting delivery
73.91	External version assisting delivery
73.92	Replacement of prolapsed umbilical cord
73.93	Incision of cervix to assist delivery
73.94	Pubiotomy to assist delivery
73.99	Other operations assisting delivery
74.0	Classical cesarean section
74.1	Low cervical cesarean section
74.2	Extraperitoneal cesarean section
74.3	Removal of extratubal ectopic pregnancy
74.4	Cesarean section of other specified type
74.9	Cesarean section of unspecified type
74.91	Hysterotomy to terminate pregnancy
74.99	Other cesarean section of unspecified type
75.4	Manual removal of retained placenta
75.5	Repair of current obstetric laceration of uterus
75.6	Repair of other current obstetric laceration
75.7	Manual exploration of uterine cavity, postpartum
75.9	Other obstetric operations

Appendix B

Optum

MarketScan

BEFORE PS MATCHING




Figure 29: Pre-matching propensity score overlap

The c-statistics for the propensity score model, pre-matching was 0.811. The post-matching c-statistic was 0.562.




Figure 29: Pre-matching propensity score overlap

The c-statistics for the propensity score model, pre-matching was 0.795. The post-matching c-statistic was 0.535.

AFTER PS MATCHING




Figure 30: Post-matching propensity score overlap




Figure 30: Post-matching propensity score overlap

Appendix B

	Optum			Marketscan			Pooled		
	Ticagrelor	Prasugrel	St. Diff	Ticagrelor	Prasugrel	St. Diff	Ticagrelor	Prasugrel	St. Diff
Number of patients	6,722	4,085		9,025	8,557		15,747	12,642	
Quarter/Year of Cohort Entry Date									
...Q3 2011; n (%)	1 (0.0%)	169 (4.1%)	-0.2924	2 (0.0%)	478 (5.6%)	-0.3444	003 (0.0%)	647 (5.1%)	-0.328
...Q4 2011; n (%)	2 (0.0%)	195 (4.8%)	-0.3176	19 (0.2%)	644 (7.5%)	-0.3864	021 (0.1%)	839 (6.6%)	-0.367
...Q1 2012; n (%)	11 (0.2%)	165 (4.0%)	-0.2674	51 (0.6%)	695 (8.1%)	-0.3741	062 (0.4%)	860 (6.8%)	-0.349
...Q2 2012; n (%)	30 (0.4%)	187 (4.6%)	-0.2715	104 (1.2%)	607 (7.1%)	-0.2991	134 (0.9%)	794 (6.3%)	-0.293
...Q3 2012; n (%)	44 (0.7%)	181 (4.4%)	-0.2363	142 (1.6%)	621 (7.3%)	-0.2791	186 (1.2%)	802 (6.3%)	-0.271
...Q4 2012; n (%)	42 (0.6%)	177 (4.3%)	-0.2411	177 (2.0%)	557 (6.5%)	-0.2245	219 (1.4%)	734 (5.8%)	-0.238
...Q1 2013; n (%)	80 (1.2%)	168 (4.1%)	-0.1813	172 (1.9%)	373 (4.4%)	-0.1435	252 (1.6%)	541 (4.3%)	-0.160
...Q2 2013; n (%)	95 (1.4%)	143 (3.5%)	-0.1362	196 (2.2%)	302 (3.5%)	-0.0782	291 (1.8%)	445 (3.5%)	-0.106
...Q3 2013; n (%)	75 (1.1%)	147 (3.6%)	-0.1656	255 (2.8%)	376 (4.4%)	-0.0860	330 (2.1%)	523 (4.1%)	-0.116
...Q4 2013; n (%)	82 (1.2%)	139 (3.4%)	-0.1472	275 (3.0%)	315 (3.7%)	-0.0389	357 (2.3%)	454 (3.6%)	-0.077
...Q1 2014; n (%)	81 (1.2%)	122 (3.0%)	-0.1258	245 (2.7%)	296 (3.5%)	-0.0462	326 (2.1%)	418 (3.3%)	-0.074
...Q2 2014; n (%)	92 (1.4%)	126 (3.1%)	-0.1148	319 (3.5%)	301 (3.5%)	0.0000	411 (2.6%)	427 (3.4%)	-0.047
...Q3 2014; n (%)	109 (1.6%)	117 (2.9%)	-0.0877	399 (4.4%)	312 (3.6%)	0.0408	508 (3.2%)	429 (3.4%)	-0.011
...Q4 2014; n (%)	109 (1.6%)	117 (2.9%)	-0.0877	430 (4.8%)	297 (3.5%)	0.0652	539 (3.4%)	414 (3.3%)	0.006
...Q1 2015; n (%)	92 (1.4%)	87 (2.1%)	-0.0534	335 (3.7%)	190 (2.2%)	0.0887	427 (2.7%)	277 (2.2%)	0.032
...Q2 2015; n (%)	102 (1.5%)	78 (1.9%)	-0.0309	354 (3.9%)	166 (1.9%)	0.1194	456 (2.9%)	244 (1.9%)	0.065
...Q3 2015; n (%)	110 (1.6%)	96 (2.4%)	-0.0572	436 (4.8%)	191 (2.2%)	0.1418	546 (3.5%)	287 (2.3%)	0.072
...Q4 2015; n (%)	130 (1.9%)	124 (3.0%)	-0.0712	483 (5.4%)	234 (2.7%)	0.1373	613 (3.9%)	358 (2.8%)	0.061
...Q1 2016; n (%)	117 (1.7%)	129 (3.2%)	-0.0971	462 (5.1%)	247 (2.9%)	0.1124	579 (3.7%)	376 (3.0%)	0.039
...Q2 2016; n (%)	170 (2.5%)	118 (2.9%)	-0.0247	497 (5.5%)	231 (2.7%)	0.1416	667 (4.2%)	349 (2.8%)	0.076
...Q3 2016; n (%)	199 (3.0%)	130 (3.2%)	-0.0115	534 (5.9%)	232 (2.7%)	0.1582	733 (4.7%)	362 (2.9%)	0.094
...Q4 2016; n (%)	213 (3.2%)	133 (3.3%)	-0.0056	576 (6.4%)	225 (2.6%)	0.1841	789 (5.0%)	358 (2.8%)	0.114
...Q1 2017; n (%)	276 (4.1%)	113 (2.8%)	0.0713	524 (5.8%)	158 (1.8%)	0.2104	800 (5.1%)	271 (2.1%)	0.162
...Q2 2017; n (%)	411 (6.1%)	122 (3.0%)	0.1492	578 (6.4%)	162 (1.9%)	0.2271	989 (6.3%)	284 (2.2%)	0.204
...Q3 2017; n (%)	490 (7.3%)	125 (3.1%)	0.1900	693 (7.7%)	192 (2.2%)	0.2556	1,183 (7.5%)	317 (2.5%)	0.231
...Q4 2017; n (%)	578 (8.6%)	122 (3.0%)	0.2413	756 (8.4%)	154 (1.8%)	0.3034	1,334 (8.5%)	276 (2.2%)	0.283
...Q1 2018; n (%)	535 (8.0%)	96 (2.4%)	0.2543	11 (0.1%)	1 (0.0%)	0.0447	546 (3.5%)	097 (0.8%)	0.187
Demographics									
Age									
...mean (sd)	63.60 (11.12)	59.90 (10.02)	0.3496	58.41 (9.83)	56.88 (8.90)	0.1632	60.63 (10.40)	57.86 (9.28)	0.281
...median [IQR]	64.00 [56.00, 71.00]	60.00 [53.00, 67.00]	0.3779	59.00 [52.00, 63.00]	58.00 [51.00, 63.00]	0.1066	61.13 (10.40)	58.65 (9.28)	0.252
Gender without zero category- United									
...Males; n (%)	4,796 (71.3%)	3,152 (77.2%)	-0.1352	6,790 (75.2%)	6,835 (79.9%)	-0.0054	11,586 (73.6%)	9,987 (79.0%)	-0.127
...Females; n (%)	1,925 (28.6%)	933 (22.8%)	0.1330	2,235 (24.8%)	1,722 (20.1%)	-0.0054	4,160 (26.4%)	2,655 (21.0%)	0.127
...Missing; n (%)	1 (0.0%)	0 (0.0%)	#DIV/0!						
Region without zero category- United v3 (lumping missing)									
...Northeast; n (%)	732 (10.9%)	300 (7.3%)	0.1254	1,683 (18.6%)	1,345 (15.7%)	0.0770	2,415 (15.3%)	1,645 (13.0%)	0.066
...South; n (%)	2,955 (44.0%)	2,035 (49.8%)	-0.1164	3,993 (44.2%)	3,705 (43.3%)	0.0181	6,948 (44.1%)	5,740 (45.4%)	-0.026
...Midwest; n (%)	1,721 (25.6%)	929 (22.7%)	0.0678	2,321 (25.7%)	2,089 (24.4%)	0.0300	4,042 (25.7%)	3,018 (23.9%)	0.042
...West; n (%)	1,314 (19.5%)	821 (20.1%)	-0.0151	970 (10.7%)	1,285 (15.0%)	-0.1288	2,284 (14.5%)	2,106 (16.7%)	-0.061
Metropolitan Statistical Area - Urban (any MSA) vs Rural (non-MSA)									
...Urban; n (%)				6,388 (70.8%)	6,604 (77.2%)	-0.1463	6,388 (70.8%)	6,604 (77.2%)	-0.1463
...Rural; n (%)				710 (7.9%)	207 (2.4%)	0.2508	710 (7.9%)	207 (2.4%)	0.2508
...Unknown/Missing; n (%)				1,927 (21.4%)	1,746 (20.4%)	0.0246	1,927 (21.4%)	1,746 (20.4%)	0.0246
Commercial vs Medicare Advantage- Business Type Code									
...COM = COMMERCIAL; n (%)	3,343 (49.7%)	2,633 (64.5%)	-0.3024				3,343 (49.7%)	2,633 (64.5%)	-0.3024
...MCR = MEDICARE; n (%)	3,379 (50.3%)	1,452 (35.5%)	0.3024				3,379 (50.3%)	1,452 (35.5%)	0.3024

Appendix B

...MCD = MEDICAID; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!				0 (0.0%)	0 (0.0%)	#DIV/0!
...NONE = NO BUSINESS LINE CODE (added in 2015); n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!				0 (0.0%)	0 (0.0%)	#DIV/0!
...UNK = UNKNOWN (added in 2015); n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!				0 (0.0%)	0 (0.0%)	#DIV/0!
Commercial vs Medicare Advantage- Data Type									
...1 - Fee For Service; n (%)				6,570 (72.8%)	6,428 (75.1%)	-0.0524	6,570 (72.8%)	6,428 (75.1%)	-0.0524
...2 - Encounter; n (%)				732 (8.1%)	757 (8.8%)	-0.0252	732 (8.1%)	757 (8.8%)	-0.0252
...3 - Medicare; n (%)				1,510 (16.7%)	1,196 (14.0%)	0.0750	1,510 (16.7%)	1,196 (14.0%)	0.0750
...4 - Medicare Encounter; n (%)				213 (2.4%)	176 (2.1%)	0.0202	213 (2.4%)	176 (2.1%)	0.0202
Lifestyle factors									
Obesity; n (%)	1,853 (27.6%)	1,014 (24.8%)	0.0637	1,853 (20.5%)	1,538 (18.0%)	0.0634	3,706 (23.5%)	2,552 (20.2%)	0.080
Overweight; n (%)	480 (7.1%)	194 (4.7%)	0.1020	330 (3.7%)	161 (1.9%)	0.1093	810 (5.1%)	355 (2.8%)	0.118
Smoking; n (%)	3,323 (49.4%)	1,925 (47.1%)	0.0460	2,999 (33.2%)	2,822 (33.0%)	0.0043	6,322 (40.1%)	4,747 (37.5%)	0.053
Alcohol abuse or dependence+Drug abuse or dependence	377 (5.6%)	168 (4.1%)	0.0699	293 (3.2%)	266 (3.1%)	0.0057	670 (4.3%)	434 (3.4%)	0.047
Diabetes-related conditions									
Diabetic retinopathy; n (%)	138 (2.1%)	60 (1.5%)	0.0451	115 (1.3%)	99 (1.2%)	0.0090	253 (1.6%)	159 (1.3%)	0.025
Occurrence of Diabetic Neuropathy v2 Copy; n (%)	463 (6.9%)	185 (4.5%)	0.1037	318 (3.5%)	249 (2.9%)	0.0341	781 (5.0%)	434 (3.4%)	0.080
Occurrence of diabetic nephropathy V3 with ICD10 Copy; n (%)	386 (5.7%)	132 (3.2%)	0.1215	219 (2.4%)	132 (1.5%)	0.0651	605 (3.8%)	264 (2.1%)	0.101
Hypoglycemia v2; n (%)	21 (0.3%)	36 (0.9%)	-0.0778	71 (0.8%)	79 (0.9%)	-0.0109	092 (0.6%)	115 (0.9%)	-0.035
Hyperglycemia; n (%)	527 (7.8%)	318 (7.8%)	0.0000	563 (6.2%)	438 (5.1%)	0.0477	1,090 (6.9%)	756 (6.0%)	0.037
Disorders of fluid electrolyte and acid-base balance; n (%)	968 (14.4%)	461 (11.3%)	0.0927	815 (9.0%)	691 (8.1%)	0.0322	1,783 (11.3%)	1,152 (9.1%)	0.073
Hyperosmolar hyperglycemic nonketotic syndrome (HONK)	21 (0.3%)	12 (0.3%)	0.0000	8 (0.1%)	10 (0.1%)	0.0000	029 (0.2%)	022 (0.2%)	0.000
Diabetic Foot; n (%)	57 (0.8%)	27 (0.7%)	0.0116	45 (0.5%)	54 (0.6%)	-0.0135	102 (0.6%)	081 (0.6%)	0.000
Skin infections v2; n (%)	212 (3.2%)	134 (3.3%)	-0.0056	265 (2.9%)	261 (3.1%)	-0.0117	477 (3.0%)	395 (3.1%)	-0.006
Erectile dysfunction; n (%)	198 (2.9%)	141 (3.5%)	-0.0341	244 (2.7%)	198 (2.3%)	0.0256	442 (2.8%)	339 (2.7%)	0.006
Diabetes with unspecified complication; n (%)	231 (3.4%)	84 (2.1%)	0.0796	223 (2.5%)	184 (2.2%)	0.0198	454 (2.9%)	268 (2.1%)	0.051
Diabetes mellitus without mention of complications; n (%)	2,290 (34.1%)	1,403 (34.3%)	-0.0042	2,797 (31.0%)	2,784 (32.5%)	-0.0322	5,087 (32.3%)	4,187 (33.1%)	-0.017
Diabetes with peripheral circulatory disorders+Gangrene+	232 (3.5%)	66 (1.6%)	0.1207	125 (1.4%)	97 (1.1%)	0.0270	357 (2.3%)	163 (1.3%)	0.075
Diabetes with other ophthalmic manifestations+Retinal de	43 (0.6%)	14 (0.3%)	0.0448	80 (0.9%)	90 (1.1%)	-0.0201	123 (0.8%)	104 (0.8%)	0.000
Cardiovascular-related conditions									
Hypertension: 1 inpatient or 2 outpatient claims within 36	5,346 (79.5%)	3,106 (76.0%)	0.0842	6,673 (73.9%)	5,846 (68.3%)	0.1238	12,019 (76.3%)	8,952 (70.8%)	0.125
Malignant hypertension; n (%)	171 (2.5%)	190 (4.7%)	-0.1183	2,791 (30.9%)	4,225 (49.4%)	-0.3843	2,962 (18.8%)	4,415 (34.9%)	-0.369
Hyperlipidemia v2; n (%)	5,379 (80.0%)	3,348 (82.0%)	-0.0510	6,450 (71.5%)	5,864 (68.5%)	0.0655	11,829 (75.1%)	9,212 (72.9%)	0.050
Acute MI; n (%)	6,184 (92.0%)	3,877 (94.9%)	-0.1174	8,521 (94.4%)	8,293 (96.9%)	-0.1228	14,705 (93.4%)	12,170 (96.3%)	-0.131
ACS/unstable angina; n (%)	2,766 (41.1%)	1,553 (38.0%)	0.0634	3,475 (38.5%)	3,016 (35.2%)	0.0684	6,241 (39.6%)	4,569 (36.1%)	0.072
Old MI; n (%)	952 (14.2%)	510 (12.5%)	0.0500	774 (8.6%)	705 (8.2%)	0.0144	1,726 (11.0%)	1,215 (9.6%)	0.046
Stable angina; n (%)	1,583 (23.5%)	665 (16.3%)	0.1811	1,561 (17.3%)	1,077 (12.6%)	0.1321	3,144 (20.0%)	1,742 (13.8%)	0.166
Coronary atherosclerosis and other forms of chronic ische	6,461 (96.1%)	3,951 (96.7%)	-0.0322	8,365 (92.7%)	7,850 (91.7%)	0.0373	14,826 (94.2%)	11,801 (93.3%)	0.037
Ischemic stroke (w and w/o mention of cerebral infarction	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	000 (0.0%)	000 (0.0%)	#DIV/0!
TIA; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	000 (0.0%)	000 (0.0%)	#DIV/0!
Late effects of cerebrovascular disease; n (%)	26 (0.4%)	6 (0.1%)	0.0601	9 (0.1%)	9 (0.1%)	0.0000	035 (0.2%)	015 (0.1%)	0.026
Heart failure (CHF); n (%)	1,300 (19.3%)	634 (15.5%)	0.1004	1,206 (13.4%)	1,105 (12.9%)	0.0148	2,506 (15.9%)	1,739 (13.8%)	0.059
Peripheral Vascular Disease (PVD) or PVD Surgery v2; n (%)	369 (5.5%)	164 (4.0%)	0.0706	250 (2.8%)	232 (2.7%)	0.0061	619 (3.9%)	396 (3.1%)	0.044
Atrial fibrillation; n (%)	541 (8.0%)	252 (6.2%)	0.0701	454 (5.0%)	355 (4.1%)	0.0432	995 (6.3%)	607 (4.8%)	0.066
Other cardiac dysrhythmia; n (%)	2,369 (35.2%)	1,204 (29.5%)	0.1221	2,553 (28.3%)	2,010 (23.5%)	0.1097	4,922 (31.3%)	3,214 (25.4%)	0.131
Hemorrhagic stroke+Other cerebrovascular disease+Cereb	39 (0.6%)	13 (0.3%)	0.0448	28 (0.3%)	14 (0.2%)	0.0200	067 (0.4%)	027 (0.2%)	0.037
Other atherosclerosis+Cardiac conduction disorders+Other	2,572 (38.3%)	1,384 (33.9%)	0.0917	2,672 (29.6%)	2,323 (27.1%)	0.0555	5,244 (33.3%)	3,707 (29.3%)	0.086
Previous cardiac procedure (CABG or PTCA or Stent) + Hist	6,575 (97.8%)	4,012 (98.2%)	-0.0286	8,349 (92.5%)	7,936 (92.7%)	-0.0076	14,924 (94.8%)	11,948 (94.5%)	0.013
Kidney-related conditions									
Occurrence of acute renal disease v2; n (%)	533 (7.9%)	227 (5.6%)	0.0918	425 (4.7%)	294 (3.4%)	0.0660	958 (6.1%)	521 (4.1%)	0.091
Occurrence of hypertensive nephropathy; n (%)	543 (8.1%)	212 (5.2%)	0.1166	316 (3.5%)	229 (2.7%)	0.0462	859 (5.5%)	441 (3.5%)	0.097
Occurrence of miscellaneous renal insufficiency v2; n (%)	338 (5.0%)	187 (4.6%)	0.0187	272 (3.0%)	226 (2.6%)	0.0242	610 (3.9%)	413 (3.3%)	0.032

Appendix B

Occurrence of chronic renal insufficiency w/o CKD (for PS)	306 (4.6%)	164 (4.0%)	0.0296	201 (2.2%)	164 (1.9%)	0.0212	507 (3.2%)	328 (2.6%)	0.036
Chronic kidney disease Stage 1-2 (for PS); n (%)	176 (2.6%)	62 (1.5%)	0.0777	78 (0.9%)	65 (0.8%)	0.0109	254 (1.6%)	127 (1.0%)	0.053
CKD stage 3-6 + dialysis (for PS); n (%)	443 (6.6%)	146 (3.6%)	0.1367	256 (2.8%)	168 (2.0%)	0.0523	699 (4.4%)	314 (2.5%)	0.104
Bladder stones+Kidney stones (for PS); n (%)	133 (2.0%)	76 (1.9%)	0.0072	155 (1.7%)	155 (1.8%)	-0.0076	288 (1.8%)	231 (1.8%)	0.000
Urinary tract infections (UTIs); n (%)	322 (4.8%)	151 (3.7%)	0.0545	256 (2.8%)	265 (3.1%)	-0.0177	578 (3.7%)	416 (3.3%)	0.022
Edema; n (%)	230 (3.4%)	110 (2.7%)	0.0407	202 (2.2%)	159 (1.9%)	0.0212	432 (2.7%)	269 (2.1%)	0.039
Other comorbidities									
COPD; n (%)	860 (12.8%)	431 (10.6%)	0.0685	643 (7.1%)	560 (6.5%)	0.0238	1,503 (9.5%)	991 (7.8%)	0.061
Asthma; n (%)	438 (6.5%)	253 (6.2%)	0.0123	445 (4.9%)	371 (4.3%)	0.0286	883 (5.6%)	624 (4.9%)	0.031
Obstructive sleep apnea; n (%)	711 (10.6%)	388 (9.5%)	0.0366	818 (9.1%)	674 (7.9%)	0.0430	1,529 (9.7%)	1,062 (8.4%)	0.045
Pneumonia; n (%)	281 (4.2%)	136 (3.3%)	0.0474	244 (2.7%)	212 (2.5%)	0.0126	525 (3.3%)	348 (2.8%)	0.029
Hyperthyroidism + Hypothyroidism + Other disorders of th	921 (13.7%)	441 (10.8%)	0.0885	882 (9.8%)	723 (8.4%)	0.0487	1,803 (11.4%)	1,164 (9.2%)	0.072
Liver disease; n (%)	4 (0.1%)	5 (0.1%)	0.0000	3 (0.0%)	1 (0.0%)	#DIV/0!	007 (0.0%)	006 (0.0%)	#DIV/0!
Osteoarthritis; n (%)	1,078 (16.0%)	516 (12.6%)	0.0972	916 (10.1%)	716 (8.4%)	0.0587	1,994 (12.7%)	1,232 (9.7%)	0.095
Other arthritis, arthropathies and musculoskeletal pain; n	2,166 (32.2%)	1,211 (29.6%)	0.0563	2,538 (28.1%)	2,206 (25.8%)	0.0519	4,704 (29.9%)	3,417 (27.0%)	0.064
Dorsopathies; n (%)	1,508 (22.4%)	880 (21.5%)	0.0217	1,749 (19.4%)	1,486 (17.4%)	0.0516	3,257 (20.7%)	2,366 (18.7%)	0.050
Fractures; n (%)	136 (2.0%)	68 (1.7%)	0.0223	146 (1.6%)	117 (1.4%)	0.0165	282 (1.8%)	185 (1.5%)	0.024
Falls v2; n (%)	127 (1.9%)	45 (1.1%)	0.0659	56 (0.6%)	35 (0.4%)	0.0284	183 (1.2%)	080 (0.6%)	0.064
Osteoporosis; n (%)	197 (2.9%)	80 (2.0%)	0.0582	120 (1.3%)	72 (0.8%)	0.0491	317 (2.0%)	152 (1.2%)	0.064
Depression; n (%)	635 (9.4%)	382 (9.4%)	0.0000	575 (6.4%)	566 (6.6%)	-0.0081	1,210 (7.7%)	948 (7.5%)	0.008
Anxiety; n (%)	875 (13.0%)	465 (11.4%)	0.0489	804 (8.9%)	608 (7.1%)	0.0664	1,679 (10.7%)	1,073 (8.5%)	0.075
Sleep_Disorder; n (%)	255 (3.8%)	315 (7.7%)	-0.1681	477 (5.3%)	702 (8.2%)	-0.1158	732 (4.6%)	1,017 (8.0%)	-0.140
Dementia; n (%)	118 (1.8%)	34 (0.8%)	0.0884	46 (0.5%)	31 (0.4%)	0.0149	164 (1.0%)	065 (0.5%)	0.058
Delirium; n (%)	60 (0.9%)	27 (0.7%)	0.0225	44 (0.5%)	33 (0.4%)	0.0149	104 (0.7%)	060 (0.5%)	0.026
Psychosis; n (%)	37 (0.6%)	19 (0.5%)	0.0135	25 (0.3%)	17 (0.2%)	0.0200	062 (0.4%)	036 (0.3%)	0.017
Use of medications									
Use of ACE inhibitors; n (%)	3,343 (49.7%)	2,234 (54.7%)	-0.1002	4,901 (54.3%)	4,985 (58.3%)	-0.0807	8,244 (52.4%)	7,219 (57.1%)	-0.095
Use of ARBs; n (%)	1,464 (21.8%)	735 (18.0%)	0.0953	1,721 (19.1%)	1,420 (16.6%)	0.0653	3,185 (20.2%)	2,155 (17.0%)	0.082
Use of Loop Diuretics - United; n (%)	620 (9.2%)	250 (6.1%)	0.1168	536 (5.9%)	483 (5.6%)	0.0129	1,156 (7.3%)	733 (5.8%)	0.061
Use of other diuretics- United; n (%)	273 (4.1%)	151 (3.7%)	0.0207	348 (3.9%)	318 (3.7%)	0.0105	621 (3.9%)	469 (3.7%)	0.010
Use of nitrates-United; n (%)	2,800 (41.7%)	1,806 (44.2%)	-0.0505	3,934 (43.6%)	3,837 (44.8%)	-0.0242	6,734 (42.8%)	5,643 (44.6%)	-0.036
Use of other hypertension drugs; n (%)	295 (4.4%)	145 (3.5%)	0.0462	292 (3.2%)	293 (3.4%)	-0.0112	587 (3.7%)	438 (3.5%)	0.011
Use of digoxin- United; n (%)	52 (0.8%)	34 (0.8%)	0.0000	40 (0.4%)	49 (0.6%)	-0.0284	092 (0.6%)	083 (0.7%)	-0.012
Use of Anti-arrhythmics; n (%)	144 (2.1%)	71 (1.7%)	0.0293	122 (1.4%)	159 (1.9%)	-0.0393	266 (1.7%)	230 (1.8%)	-0.008
Use of COPD/asthma meds- United; n (%)	844 (12.6%)	485 (11.9%)	0.0214	971 (10.8%)	928 (10.8%)	0.0000	1,815 (11.5%)	1,413 (11.2%)	0.009
Use of statins; n (%)	6,084 (90.5%)	3,736 (91.5%)	-0.0349	8,217 (91.0%)	7,798 (91.1%)	-0.0035	14,301 (90.8%)	11,534 (91.2%)	-0.014
Use of other lipid-lowering drugs; n (%)	442 (6.6%)	340 (8.3%)	-0.0648	695 (7.7%)	801 (9.4%)	-0.0608	1,137 (7.2%)	1,141 (9.0%)	-0.066
Use of antiplatelet agents; n (%)	532 (7.9%)	340 (8.3%)	-0.0147	616 (6.8%)	695 (8.1%)	-0.0495	1,148 (7.3%)	1,035 (8.2%)	-0.034
Use of oral anticoagulants (Dabigatran, Rivaroxaban, Apix	230 (3.4%)	81 (2.0%)	0.0865	230 (2.5%)	210 (2.5%)	0.0000	460 (2.9%)	291 (2.3%)	0.038
Use of heparin and other low-molecular weight heparins;	27 (0.4%)	11 (0.3%)	0.0169	0 (0.0%)	0 (0.0%)	#DIV/0!	027 (0.2%)	011 (0.1%)	0.026
Use of NSAIDs; n (%)	996 (14.8%)	539 (13.2%)	0.0461	1,386 (15.4%)	1,189 (13.9%)	0.0424	2,382 (15.1%)	1,728 (13.7%)	0.040
Use of oral corticosteroids; n (%)	1,091 (16.2%)	556 (13.6%)	0.0731	1,337 (14.8%)	1,173 (13.7%)	0.0315	2,428 (15.4%)	1,729 (13.7%)	0.048
Use of bisphosphonate (United); n (%)	75 (1.1%)	33 (0.8%)	0.0309	46 (0.5%)	42 (0.5%)	0.0000	121 (0.8%)	075 (0.6%)	0.024
Use of opioids- United; n (%)	1,316 (19.6%)	924 (22.6%)	-0.0736	1,852 (20.5%)	1,859 (21.7%)	-0.0294	3,168 (20.1%)	2,783 (22.0%)	-0.047
Use of antidepressants; n (%)	1,106 (16.5%)	650 (15.9%)	0.0163	1,388 (15.4%)	1,229 (14.4%)	0.0281	2,494 (15.8%)	1,879 (14.9%)	0.025
Use of antipsychotics; n (%)	93 (1.4%)	36 (0.9%)	0.0469	86 (1.0%)	65 (0.8%)	0.0212	179 (1.1%)	101 (0.8%)	0.031
Use of anticonvulsants; n (%)	635 (9.4%)	293 (7.2%)	0.0798	589 (6.5%)	494 (5.8%)	0.0291	1,224 (7.8%)	787 (6.2%)	0.063
Use of Benzos- United; n (%)	608 (9.0%)	383 (9.4%)	-0.0138	881 (9.8%)	790 (9.2%)	0.0205	1,489 (9.5%)	1,173 (9.3%)	0.007
Use of anxiolytics/hypnotics- United; n (%)	285 (4.2%)	226 (5.5%)	-0.0605	443 (4.9%)	467 (5.5%)	-0.0270	728 (4.6%)	693 (5.5%)	-0.041
Use of dementia meds- United; n (%)	44 (0.7%)	19 (0.5%)	0.0259	27 (0.3%)	8 (0.1%)	0.0448	071 (0.5%)	027 (0.2%)	0.051

Appendix B

Use of antiparkinsonian meds- United; n (%)	118 (1.8%)	46 (1.1%)	0.0586	101 (1.1%)	71 (0.8%)	0.0309	219 (1.4%)	117 (0.9%)	0.047
Use of glucose test strips; n (%)	86 (1.3%)	48 (1.2%)	0.0090	116 (1.3%)	113 (1.3%)	0.0000	202 (1.3%)	161 (1.3%)	0.000
Use of thiazide- United; n (%)	537 (8.0%)	288 (7.1%)	0.0341	606 (6.7%)	544 (6.4%)	0.0121	1,143 (7.3%)	832 (6.6%)	0.028
Use of beta blockers; n (%)	5,753 (85.6%)	3,550 (86.9%)	-0.0378	7,873 (87.2%)	7,618 (89.0%)	-0.0556	13,626 (86.5%)	11,168 (88.3%)	-0.054
Use of calcium channel blockers; n (%)	1,357 (20.2%)	706 (17.3%)	0.0744	1,642 (18.2%)	1,370 (16.0%)	0.0585	2,999 (19.0%)	2,076 (16.4%)	0.068
Use of aspirin; n (%)	1,042 (15.5%)	369 (9.0%)	0.1992	1,807 (20.0%)	925 (10.8%)	0.2570	2,849 (18.1%)	1,294 (10.2%)	0.228
Use of Low Intensity Statins; n (%)	1,500 (22.3%)	1,250 (30.6%)	-0.1890	2,143 (23.7%)	2,734 (32.0%)	-0.1860	3,643 (23.1%)	3,984 (31.5%)	-0.189
Use of High Intensity Statins; n (%)	5,326 (79.2%)	2,878 (70.5%)	0.2015	7,021 (77.8%)	5,772 (67.5%)	0.2326	12,347 (78.4%)	8,650 (68.4%)	0.228
Use of Sympathomimetic agents; n (%)	66 (1.0%)	45 (1.1%)	-0.0098	121 (1.3%)	85 (1.0%)	0.0281	187 (1.2%)	130 (1.0%)	0.019
Use of CNS stimulants; n (%)	27 (0.4%)	13 (0.3%)	0.0169	44 (0.5%)	54 (0.6%)	-0.0135	071 (0.5%)	067 (0.5%)	0.000
All antidiabetic medications except Insulin; n (%)	1,603 (23.8%)	915 (22.4%)	0.0332	2,040 (22.6%)	1,948 (22.8%)	-0.0048	3,643 (23.1%)	2,863 (22.6%)	0.012
DM Medications - Insulin Copy; n (%)	616 (9.2%)	352 (8.6%)	0.0211	817 (9.1%)	765 (8.9%)	0.0070	1,433 (9.1%)	1,117 (8.8%)	0.011
Use of estrogens, progestins, androgens; n (%)	195 (2.9%)	153 (3.7%)	-0.0448	381 (4.2%)	381 (4.5%)	-0.0147	576 (3.7%)	534 (4.2%)	-0.026
Use of Angiogenesis inhibitors; n (%)	4 (0.1%)	0 (0.0%)	0.0447	1 (0.0%)	0 (0.0%)	#DIV/0!	005 (0.0%)	000 (0.0%)	#DIV/0!
Use of Oral Immunosuppressants; n (%)	7 (0.1%)	4 (0.1%)	0.0000	18 (0.2%)	15 (0.2%)	0.0000	025 (0.2%)	019 (0.2%)	0.000
Use of fondaparinux or Bivalirudin; n (%)	0 (0.0%)	2 (0.0%)	#DIV/0!	0 (0.0%)	2 (0.0%)	#DIV/0!	000 (0.0%)	004 (0.0%)	#DIV/0!
Use of other direct thrombin inhibitors (lepirudin, desirudin); n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	000 (0.0%)	000 (0.0%)	#DIV/0!
Use of CYP inhibitors; n (%)	1,063 (15.8%)	645 (15.8%)	0.0000	1,373 (15.2%)	1,295 (15.1%)	0.0028	2,436 (15.5%)	1,940 (15.3%)	0.006
Use of CYP inducers; n (%)	19 (0.3%)	14 (0.3%)	0.0000	27 (0.3%)	33 (0.4%)	-0.0169	046 (0.3%)	047 (0.4%)	-0.017
Burden of disease/Healthcare utilization									
Combined comorbidity score, 180 days Copy									
...mean (sd)	1.51 (1.96)	0.93 (1.74)	0.3130	0.74 (1.54)	0.50 (1.43)	0.1615	1.07 (1.73)	0.64 (1.54)	0.263
...median [IQR]	1.00 [0.00, 3.00]	1.00 [0.00, 2.00]	0.0000	0.00 [0.00, 2.00]	0.00 [-1.00, 1.00]	0.0000	0.43 (1.73)	0.32 (1.54)	0.067
Frailty Score (mean): Empirical Version 365 days, v2									
...mean (sd)	0.18 (0.04)	0.17 (0.04)	0.2500	0.17 (0.03)	0.17 (0.03)	0.0000	0.17 (0.03)	0.17 (0.03)	0.000
...median [IQR]	0.17 [0.15, 0.20]	0.17 [0.15, 0.19]	0.0000	0.16 [0.15, 0.19]	0.16 [0.14, 0.18]	0.0000	0.16 (0.03)	0.16 (0.03)	0.000
Total N distinct ICD9/ICD10 diagnoses at the 3rd digit level									
...mean (sd)	11.01 (9.01)	6.41 (8.19)	0.5343	7.66 (8.06)	4.42 (7.09)	0.4268	9.09 (8.48)	5.06 (7.46)	0.505
...median [IQR]	10.00 [4.00, 17.00]	3.00 [0.00, 11.00]	0.8130	6.00 [0.00, 14.00]	0.00 [0.00, 9.00]	0.7905	7.71 (8.48)	0.97 (7.46)	0.844
HAS-BLED Score (ICD-9 and ICD-10), 180 days									
...mean (sd)	3.50 (0.58)	3.35 (0.56)	0.2631	3.18 (0.48)	3.14 (0.44)	0.0869	3.32 (0.53)	3.21 (0.48)	0.218
...median [IQR]	3.00 [3.00, 4.00]	3.00 [3.00, 4.00]	0.0000	3.00 [3.00, 3.00]	3.00 [3.00, 3.00]	0.0000	3.00 (0.53)	3.00 (0.48)	0.000
number of different/distinct medication prescriptions									
...mean (sd)	8.94 (4.49)	8.53 (4.32)	0.0931	8.71 (4.31)	8.50 (4.18)	0.0495	8.81 (4.39)	8.51 (4.23)	0.070
...median [IQR]	8.00 [6.00, 11.00]	8.00 [5.00, 11.00]	0.0000	8.00 [6.00, 11.00]	8.00 [5.00, 11.00]	0.0000	8.00 (4.39)	8.00 (4.23)	0.000
Any hospitalization within prior 30 days; n (%)	6,722 (100.0%)	4,085 (100.0%)	#DIV/0!	9,025 (100.0%)	8,557 (100.0%)	#DIV/0!	15,747 (100.0%)	12,642 (100.0%)	#DIV/0!
Number of Hospitalizations									
...mean (sd)	1.08 (0.30)	1.08 (0.32)	0.0000	1.06 (0.26)	1.08 (0.29)	-0.0726	1.07 (0.28)	1.08 (0.30)	-0.034
...median [IQR]	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	0.0000	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	0.0000	1.00 (0.28)	1.00 (0.30)	0.000
Number of hospital days									
...mean (sd)	3.60 (1.94)	3.61 (1.94)	-0.0052	3.42 (1.84)	3.60 (1.80)	-0.0989	3.50 (1.88)	3.60 (1.85)	-0.054
...median [IQR]	3.00 [3.00, 4.00]	3.00 [3.00, 4.00]	0.0000	3.00 [3.00, 4.00]	3.00 [3.00, 4.00]	0.0000	3.00 (1.88)	3.00 (1.85)	0.000
Number of Emergency Department (ED) visits v3									
...mean (sd)	1.07 (1.30)	1.06 (1.32)	0.0076	3.52 (5.63)	3.31 (6.05)	0.0359	2.47 (4.35)	2.58 (5.03)	-0.023
...median [IQR]	1.00 [0.00, 1.00]	1.00 [0.00, 1.00]	0.0000	2.00 [0.00, 4.00]	2.00 [0.00, 4.00]	0.0000	1.57 (4.35)	1.68 (5.03)	-0.023
Number of Office visits									
...mean (sd)	3.12 (3.16)	2.92 (3.33)	0.0616	2.77 (2.94)	2.67 (2.93)	0.0341	2.92 (3.04)	2.75 (3.06)	0.056
...median [IQR]	2.00 [1.00, 4.00]	2.00 [1.00, 4.00]	0.0000	2.00 [1.00, 4.00]	2.00 [1.00, 4.00]	0.0000	2.00 (3.04)	2.00 (3.06)	0.000
Number of internal medicine/family medicine visits									
...mean (sd)	7.11 (10.84)	5.72 (9.60)	0.1358	3.93 (5.98)	3.75 (6.60)	0.0286	5.29 (8.41)	4.39 (7.70)	0.112
...median [IQR]	4.00 [1.00, 9.00]	3.00 [0.00, 7.00]	0.0977	2.00 [0.00, 5.00]	2.00 [0.00, 5.00]	0.0000	2.85 (8.41)	2.32 (7.70)	0.066

Appendix B

Number of Cardiologist visits									
...mean (sd)	8.41 (5.38)	8.07 (4.88)	0.0662	1.06 (2.17)	0.97 (2.18)	0.0414	4.20 (3.88)	3.26 (3.30)	0.261
...median [IQR]	8.00 [5.00, 11.00]	7.00 [5.00, 10.00]	0.1947	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.0000	3.41 (3.88)	2.26 (3.30)	0.319
Number electrocardiograms received v2									
...mean (sd)	3.28 (2.45)	3.32 (2.52)	-0.0161	0.98 (1.33)	1.05 (1.40)	-0.0513	1.96 (1.89)	1.78 (1.84)	0.097
...median [IQR]	3.00 [2.00, 4.00]	3.00 [2.00, 5.00]	0.0000	1.00 [0.00, 1.00]	1.00 [0.00, 2.00]	0.0000	1.85 (1.89)	1.65 (1.84)	0.107
Number of BNP tests									
...mean (sd)	0.10 (0.37)	0.10 (0.37)	0.0000	0.12 (0.38)	0.13 (0.39)	-0.0260	0.11 (0.38)	0.12 (0.38)	-0.026
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.0000	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.0000	0.00 (0.38)	0.00 (0.38)	0.000
Number of Cardiac biomarkers tests (troponin, CK-MBs, My									
...mean (sd)	0.68 (1.66)	0.76 (1.77)	-0.0466	0.69 (1.61)	0.83 (1.79)	-0.0822	0.69 (1.63)	0.81 (1.78)	-0.070
...median [IQR]	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.0000	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.0000	0.00 (1.63)	0.00 (1.78)	0.000
Number of Ambulatory Blood pressure monitoring tests									
...mean (sd)	0.00 (0.02)	0.00 (0.02)	0.0000	0.00 (0.04)	0.00 (0.03)	0.0000	0.00 (0.03)	0.00 (0.03)	0.000
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.0000	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.0000	0.00 (0.03)	0.00 (0.03)	0.000
N of days on antihypertensive medications during baseline									
...mean (sd)	81.19 (79.68)	71.98 (77.47)	0.1172	74.18 (78.62)	68.85 (77.22)	0.0684	77.17 (79.07)	69.86 (77.30)	0.093
...median [IQR]	62.50 [1.00, 172.00]	21.00 [1.00, 164.00]	0.5281	29.00 [1.00, 167.00]	8.00 [1.00, 162.00]	0.2695	43.30 (79.07)	12.20 (77.30)	0.398
N of days in database anytime prior									
...mean (sd)	1,685.49 (1,370.91)	1,619.30 (1,246.27)	0.0505	2,118.05 (1,473.24)	1,786.28 (1,260.85)	0.2420	1933.40 (1430.45)	1732.32 (1256.16)	0.149
...median [IQR]	1,246.00 [606.00, 2,4	1,242.00 [605.00, 2,4	0.0031	1,804.00 [830.00, 3,2	1,443.00 [726.00, 2,7	0.2633	1565.80 (1430.45)	1378.05 (1256.16)	0.139
Mean Copay for per prescription cost (charges in U.S. \$) (1									
...mean (sd)	21.80 (31.56)	25.04 (28.00)	-0.1086	15.43 (20.81)	18.99 (25.39)	-0.1534	18.15 (25.95)	20.94 (26.26)	-0.107
...median [IQR]	13.33 [5.00, 27.78]	17.11 [7.40, 33.33]	-0.1267	10.00 [1.98, 21.01]	12.44 [4.50, 25.29]	-0.1051	11.42 (25.95)	13.95 (26.26)	-0.097
...Missing; n (%)	879 (13.1%)	638 (15.6%)	-0.0714	1,391 (15.4%)	1,411 (16.5%)	-0.0300	2,270 (14.4%)	2,049 (16.2%)	-0.050
Duration of index hospitalization (i.e. anchor hospitalizatio									
...mean (sd)	1.00 (0.00)	1.00 (0.00)	#DIV/0!	1.00 (0.00)	1.00 (0.00)	#DIV/0!	1.00 (0.00)	1.00 (0.00)	#DIV/0!
...median [IQR]	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	#DIV/0!	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	#DIV/0!	1.00 (0.00)	1.00 (0.00)	#DIV/0!
N of Generic name drugs									
...mean (sd)	13.03 (11.49)	11.70 (10.59)	0.1204	11.38 (9.78)	10.30 (8.90)	0.1155	12.08 (10.54)	10.75 (9.48)	0.133
...median [IQR]	10.00 [5.00, 17.00]	8.00 [4.00, 16.00]	0.1810	9.00 [5.00, 15.00]	8.00 [4.00, 14.00]	0.1069	9.43 (10.54)	8.00 (9.48)	0.143
N of Brand name drugs									
...mean (sd)	3.08 (3.59)	3.51 (4.09)	-0.1117	3.42 (3.62)	3.99 (4.24)	-0.1446	3.27 (3.61)	3.83 (4.19)	-0.143
...median [IQR]	2.00 [1.00, 4.00]	2.00 [1.00, 4.00]	0.0000	2.00 [1.00, 4.00]	2.00 [1.00, 5.00]	0.0000	2.00 (3.61)	2.00 (4.19)	0.000
Number of D-dimer tests									
...mean (sd)	0.06 (0.25)	0.06 (0.25)	0.0000	0.07 (0.28)	0.07 (0.29)	0.0000	0.07 (0.27)	0.07 (0.28)	0.000
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.0000	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.0000	0.00 (0.27)	0.00 (0.28)	0.000
Numbe of CRP, high-sensitivity CRP tests									
...mean (sd)	0.05 (0.30)	0.04 (0.33)	0.0317	0.04 (0.27)	0.04 (0.26)	0.0000	0.04 (0.28)	0.04 (0.28)	0.000
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.0000	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.0000	0.00 (0.28)	0.00 (0.28)	0.000
Number of PT or aPTTt tests									
...mean (sd)	0.39 (1.09)	0.36 (0.99)	0.0288	0.37 (0.92)	0.44 (1.04)	-0.0713	0.38 (1.00)	0.41 (1.02)	-0.030
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.0000	0.00 [0.00, 0.00]	0.00 [0.00, 1.00]	0.0000	0.00 (1.00)	0.00 (1.02)	0.000
Number of Bleeding time tests									
...mean (sd)	0.00 (0.02)	0.00 (0.00)	0.0000	0.00 (0.01)	0.00 (0.00)	0.0000	0.00 (0.02)	0.00 (0.00)	0.000
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.0000	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.0000	0.00 (0.02)	0.00 (0.00)	0.000
Occurrence of creatinine tests ordered (for PS); n (%)	227 (3.4%)	107 (2.6%)	0.0469	228 (2.5%)	265 (3.1%)	-0.0364	455 (2.9%)	372 (2.9%)	0.000
Cardiovascular stress test; n (%)	15 (0.2%)	6 (0.1%)	0.0258	15 (0.2%)	15 (0.2%)	0.0000	030 (0.2%)	021 (0.2%)	0.000
Echocardiogram; n (%)	5,099 (75.9%)	2,718 (66.5%)	0.2087	6,478 (71.8%)	5,447 (63.7%)	0.1739	11,577 (73.5%)	8,165 (64.6%)	0.193
Colonoscopy; n (%)	222 (3.3%)	152 (3.7%)	-0.0218	329 (3.6%)	294 (3.4%)	0.0109	551 (3.5%)	446 (3.5%)	0.000
Fecal occult blood (FOB) test; n (%)	163 (2.4%)	115 (2.8%)	-0.0251	224 (2.5%)	226 (2.6%)	-0.0063	387 (2.5%)	341 (2.7%)	-0.013

Appendix B

Flu vaccine; n (%)	978 (14.5%)	523 (12.8%)	0.0495	768 (8.5%)	687 (8.0%)	0.0182	1,746 (11.1%)	1,210 (9.6%)	0.049
Mammogram; n (%)	396 (5.9%)	170 (4.2%)	0.0777	369 (4.1%)	301 (3.5%)	0.0314	765 (4.9%)	471 (3.7%)	0.059
Pap smear; n (%)	132 (2.0%)	85 (2.1%)	-0.0071	174 (1.9%)	182 (2.1%)	-0.0143	306 (1.9%)	267 (2.1%)	-0.014
Pneumonia vaccine; n (%)	1,315 (19.6%)	496 (12.1%)	0.2065	754 (8.4%)	461 (5.4%)	0.1186	2,069 (13.1%)	957 (7.6%)	0.181
PSA test or Prostate exam for DRE; n (%)	1,018 (15.1%)	646 (15.8%)	-0.0194	1,125 (12.5%)	1,167 (13.6%)	-0.0327	2,143 (13.6%)	1,813 (14.3%)	-0.020
Bone mineral density; n (%)	110 (1.6%)	60 (1.5%)	0.0081	79 (0.9%)	47 (0.5%)	0.0480	189 (1.2%)	107 (0.8%)	0.040
Drug eluting stent; n (%)	998 (14.8%)	1,987 (48.6%)	-0.7796	2,503 (27.7%)	3,877 (45.3%)	-0.3718	3,501 (22.2%)	5,864 (46.4%)	-0.527
Bare metal stent; n (%)	5,844 (86.9%)	2,853 (69.8%)	0.4244	7,737 (85.7%)	4,842 (56.6%)	0.6782	13,581 (86.2%)	7,695 (60.9%)	0.599

Appendix B

	Optum			Marketscan			Pooled		
	Ticagrelor	Prasugrel	St. Diff	Ticagrelor	Prasugrel	St. Diff	Ticagrelor	Prasugrel	St. Diff
Number of patients	2,498	2,498		4,802	4,802		7,300	7,300	
Quarter/Year of Cohort Entry Date									
...Q3 2011; n (%)	1 (0.0%)	0 (0.0%)	#DIV/0!	2 (0.0%)	2 (0.0%)	#DIV/0!	003 (0.0%)	002 (0.0%)	#DIV/0!
...Q4 2011; n (%)	2 (0.1%)	2 (0.1%)	0.0000	19 (0.4%)	20 (0.4%)	0.0000	021 (0.3%)	022 (0.3%)	0.000
...Q1 2012; n (%)	11 (0.4%)	16 (0.6%)	-0.0284	51 (1.1%)	42 (0.9%)	0.0201	062 (0.8%)	058 (0.8%)	0.000
...Q2 2012; n (%)	30 (1.2%)	23 (0.9%)	0.0294	104 (2.2%)	98 (2.0%)	0.0139	134 (1.8%)	121 (1.7%)	0.008
...Q3 2012; n (%)	44 (1.8%)	51 (2.0%)	-0.0146	142 (3.0%)	156 (3.2%)	-0.0115	186 (2.5%)	207 (2.8%)	-0.019
...Q4 2012; n (%)	42 (1.7%)	54 (2.2%)	-0.0362	177 (3.7%)	189 (3.9%)	-0.0105	219 (3.0%)	243 (3.3%)	-0.017
...Q1 2013; n (%)	78 (3.1%)	67 (2.7%)	0.0238	171 (3.6%)	176 (3.7%)	-0.0053	249 (3.4%)	243 (3.3%)	0.006
...Q2 2013; n (%)	89 (3.6%)	78 (3.1%)	0.0278	188 (3.9%)	190 (4.0%)	-0.0051	277 (3.8%)	268 (3.7%)	0.005
...Q3 2013; n (%)	70 (2.8%)	71 (2.8%)	0.0000	243 (5.1%)	253 (5.3%)	-0.0090	313 (4.3%)	324 (4.4%)	-0.005
...Q4 2013; n (%)	75 (3.0%)	73 (2.9%)	0.0059	249 (5.2%)	235 (4.9%)	0.0137	324 (4.4%)	308 (4.2%)	0.010
...Q1 2014; n (%)	77 (3.1%)	74 (3.0%)	0.0058	224 (4.7%)	223 (4.6%)	0.0047	301 (4.1%)	297 (4.1%)	0.000
...Q2 2014; n (%)	79 (3.2%)	70 (2.8%)	0.0235	258 (5.4%)	265 (5.5%)	-0.0044	337 (4.6%)	335 (4.6%)	0.000
...Q3 2014; n (%)	89 (3.6%)	76 (3.0%)	0.0336	278 (5.8%)	291 (6.1%)	-0.0127	367 (5.0%)	367 (5.0%)	0.000
...Q4 2014; n (%)	90 (3.6%)	78 (3.1%)	0.0278	302 (6.3%)	285 (5.9%)	0.0167	392 (5.4%)	363 (5.0%)	0.018
...Q1 2015; n (%)	67 (2.7%)	71 (2.8%)	-0.0061	186 (3.9%)	188 (3.9%)	0.0000	253 (3.5%)	259 (3.5%)	0.000
...Q2 2015; n (%)	63 (2.5%)	62 (2.5%)	0.0000	158 (3.3%)	166 (3.5%)	-0.0110	221 (3.0%)	228 (3.1%)	-0.006
...Q3 2015; n (%)	78 (3.1%)	77 (3.1%)	0.0000	205 (4.3%)	191 (4.0%)	0.0150	283 (3.9%)	268 (3.7%)	0.010
...Q4 2015; n (%)	100 (4.0%)	90 (3.6%)	0.0209	249 (5.2%)	234 (4.9%)	0.0137	349 (4.8%)	324 (4.4%)	0.019
...Q1 2016; n (%)	84 (3.4%)	91 (3.6%)	-0.0109	263 (5.5%)	244 (5.1%)	0.0179	347 (4.8%)	335 (4.6%)	0.009
...Q2 2016; n (%)	97 (3.9%)	102 (4.1%)	-0.0102	236 (4.9%)	230 (4.8%)	0.0047	333 (4.6%)	332 (4.5%)	0.005
...Q3 2016; n (%)	104 (4.2%)	112 (4.5%)	-0.0147	249 (5.2%)	232 (4.8%)	0.0184	353 (4.8%)	344 (4.7%)	0.005
...Q4 2016; n (%)	129 (5.2%)	123 (4.9%)	0.0137	216 (4.5%)	225 (4.7%)	-0.0095	345 (4.7%)	348 (4.8%)	-0.005
...Q1 2017; n (%)	100 (4.0%)	113 (4.5%)	-0.0248	141 (2.9%)	158 (3.3%)	-0.0231	241 (3.3%)	271 (3.7%)	-0.022
...Q2 2017; n (%)	110 (4.4%)	122 (4.9%)	-0.0237	159 (3.3%)	162 (3.4%)	-0.0056	269 (3.7%)	284 (3.9%)	-0.010
...Q3 2017; n (%)	119 (4.8%)	125 (5.0%)	-0.0093	173 (3.6%)	192 (4.0%)	-0.0209	292 (4.0%)	317 (4.3%)	-0.015
...Q4 2017; n (%)	107 (4.3%)	122 (4.9%)	-0.0286	158 (3.3%)	154 (3.2%)	0.0056	265 (3.6%)	276 (3.8%)	-0.011
...Q1 2018; n (%)	92 (3.7%)	96 (3.8%)	-0.0053	1 (0.0%)	1 (0.0%)	#DIV/0!	093 (1.3%)	097 (1.3%)	0.000
Demographics									
Age									
...mean (sd)	61.84 (11.27)	61.48 (10.03)	0.0337	57.39 (9.86)	57.47 (8.66)	-0.0086	58.91 (10.36)	58.84 (9.15)	0.007
...median [IQR]	62.00 [54.00, 70.00]	62.00 [55.00, 69.00]	0.0000	58.00 [51.00, 63.00]	58.00 [52.00, 63.00]	0.0000	59.37 (10.36)	59.37 (9.15)	0.000
Gender without zero category- United									
...Males; n (%)	1,877 (75.1%)	1,880 (75.3%)	-0.0046	3,759 (78.3%)	3,743 (77.9%)	0.0005	5,636 (77.2%)	5,623 (77.0%)	0.005
...Females; n (%)	621 (24.9%)	618 (24.7%)	0.0046	1,043 (21.7%)	1,059 (22.1%)	0.0005	1,664 (22.8%)	1,677 (23.0%)	-0.005
Region without zero category- United v3 (lumping missing)									
...Northeast; n (%)	234 (9.4%)	215 (8.6%)	0.0280	784 (16.3%)	779 (16.2%)	0.0027	1,018 (13.9%)	994 (13.6%)	0.009
...South; n (%)	1,185 (47.4%)	1,187 (47.5%)	-0.0020	2,159 (45.0%)	2,186 (45.5%)	-0.0100	3,344 (45.8%)	3,373 (46.2%)	-0.008
...Midwest; n (%)	576 (23.1%)	584 (23.4%)	-0.0071	1,178 (24.5%)	1,165 (24.3%)	0.0047	1,754 (24.0%)	1,749 (24.0%)	0.000
...West; n (%)	503 (20.1%)	512 (20.5%)	-0.0099	629 (13.1%)	614 (12.8%)	0.0089	1,132 (15.5%)	1,126 (15.4%)	0.003
Metropolitan Statistical Area - Urban (any MSA) vs Rural (non-MSA)									
...Urban; n (%)				3,606 (75.1%)	3,607 (75.1%)	0.0000	3,606 (75.1%)	3,607 (75.1%)	0.0000
...Rural; n (%)				204 (4.2%)	207 (4.3%)	-0.0050	204 (4.2%)	207 (4.3%)	-0.0050
...Unknown/Missing; n (%)				992 (20.7%)	988 (20.6%)	0.0025	992 (20.7%)	988 (20.6%)	0.0025
Commercial vs Medicare Advantage- Business Type Code									
...COM = COMMERCIAL; n (%)	1,370 (54.8%)	1,414 (56.6%)	-0.0362				1,370 (54.8%)	1,414 (56.6%)	-0.0362
...MCR = MEDICARE; n (%)	1,128 (45.2%)	1,084 (43.4%)	0.0362				1,128 (45.2%)	1,084 (43.4%)	0.0362
...MCD = MEDICAID; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!				0 (0.0%)	0 (0.0%)	#DIV/0!

Appendix B

...NONE = NO BUSINESS LINE CODE (added in 2015); n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!				0 (0.0%)	0 (0.0%)	#DIV/0!
...UNK = UNKNOWN (added in 2015); n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!				0 (0.0%)	0 (0.0%)	#DIV/0!
Commercial vs Medicare Advantage- Data Type									
...1 - Fee For Service; n (%)				3,556 (74.1%)	3,566 (74.3%)	-0.0046	3,556 (74.1%)	3,566 (74.3%)	-0.0046
...2 - Encounter; n (%)				419 (8.7%)	418 (8.7%)	0.0000	419 (8.7%)	418 (8.7%)	0.0000
...3 - Medicare; n (%)				725 (15.1%)	714 (14.9%)	0.0056	725 (15.1%)	714 (14.9%)	0.0056
...4 - Medicare Encounter; n (%)				102 (2.1%)	104 (2.2%)	-0.0069	102 (2.1%)	104 (2.2%)	-0.0069
Lifestyle factors									
Obesity; n (%)	647 (25.9%)	658 (26.3%)	-0.0091	966 (20.1%)	937 (19.5%)	0.0151	1,613 (22.1%)	1,595 (21.8%)	0.007
Overweight; n (%)	134 (5.4%)	155 (6.2%)	-0.0342	111 (2.3%)	119 (2.5%)	-0.0131	245 (3.4%)	274 (3.8%)	-0.021
Smoking; n (%)	1,220 (48.8%)	1,220 (48.8%)	0.0000	1,586 (33.0%)	1,579 (32.9%)	0.0021	2,806 (38.4%)	2,799 (38.3%)	0.002
Alcohol abuse or dependence+Drug abuse or dependence	133 (5.3%)	120 (4.8%)	0.0228	157 (3.3%)	150 (3.1%)	0.0114	290 (4.0%)	270 (3.7%)	0.016
Diabetes-related conditions									
Diabetic retinopathy; n (%)	39 (1.6%)	38 (1.5%)	0.0081	61 (1.3%)	56 (1.2%)	0.0090	100 (1.4%)	094 (1.3%)	0.009
Occurrence of Diabetic Neuropathy v2 Copy; n (%)	138 (5.5%)	141 (5.6%)	-0.0044	158 (3.3%)	159 (3.3%)	0.0000	296 (4.1%)	300 (4.1%)	0.000
Occurrence of diabetic nephropathy V3 with ICD10 Copy; n (%)	97 (3.9%)	112 (4.5%)	-0.0299	79 (1.6%)	86 (1.8%)	-0.0155	176 (2.4%)	198 (2.7%)	-0.019
Hypoglycemia v2; n (%)	18 (0.7%)	15 (0.6%)	0.0124	50 (1.0%)	49 (1.0%)	0.0000	068 (0.9%)	064 (0.9%)	0.000
Hyperglycemia; n (%)	205 (8.2%)	199 (8.0%)	0.0073	290 (6.0%)	294 (6.1%)	-0.0042	495 (6.8%)	493 (6.8%)	0.000
Disorders of fluid electrolyte and acid-base balance; n (%)	302 (12.1%)	310 (12.4%)	-0.0092	432 (9.0%)	416 (8.7%)	0.0106	734 (10.1%)	726 (9.9%)	0.007
Hyperosmolar hyperglycemic nonketotic syndrome (HONK)	9 (0.4%)	9 (0.4%)	0.0000	3 (0.1%)	6 (0.1%)	0.0000	012 (0.2%)	015 (0.2%)	0.000
Diabetic Foot; n (%)	24 (1.0%)	20 (0.8%)	0.0212	29 (0.6%)	30 (0.6%)	0.0000	053 (0.7%)	050 (0.7%)	0.000
Skin infections v2; n (%)	83 (3.3%)	83 (3.3%)	0.0000	157 (3.3%)	151 (3.1%)	0.0114	240 (3.3%)	234 (3.2%)	0.006
Erectile dysfunction; n (%)	80 (3.2%)	82 (3.3%)	-0.0056	138 (2.9%)	129 (2.7%)	0.0121	218 (3.0%)	211 (2.9%)	0.006
Diabetes with unspecified complication; n (%)	60 (2.4%)	65 (2.6%)	-0.0128	117 (2.4%)	118 (2.5%)	-0.0065	177 (2.4%)	183 (2.5%)	-0.006
Diabetes mellitus without mention of complications; n (%)	821 (32.9%)	854 (34.2%)	-0.0275	1,551 (32.3%)	1,561 (32.5%)	-0.0043	2,372 (32.5%)	2,415 (33.1%)	-0.013
Diabetes with peripheral circulatory disorders+Gangrene+	44 (1.8%)	54 (2.2%)	-0.0286	55 (1.1%)	58 (1.2%)	-0.0094	099 (1.4%)	112 (1.5%)	-0.008
Diabetes with other ophthalmic manifestations+Retinal de	10 (0.4%)	11 (0.4%)	0.0000	48 (1.0%)	45 (0.9%)	0.0103	058 (0.8%)	056 (0.8%)	0.000
Cardiovascular-related conditions									
Hypertension: 1 inpatient or 2 outpatient claims within 36	1,929 (77.2%)	1,929 (77.2%)	0.0000	3,455 (71.9%)	3,453 (71.9%)	0.0000	5,384 (73.8%)	5,382 (73.7%)	0.002
Malignant hypertension; n (%)	109 (4.4%)	104 (4.2%)	0.0099	2,019 (42.0%)	2,011 (41.9%)	0.0020	2,128 (29.2%)	2,115 (29.0%)	0.004
Hyperlipidemia v2; n (%)	2,030 (81.3%)	2,020 (80.9%)	0.0102	3,419 (71.2%)	3,412 (71.1%)	0.0022	5,449 (74.6%)	5,432 (74.4%)	0.005
Acute MI; n (%)	2,312 (92.6%)	2,315 (92.7%)	-0.0038	4,566 (95.1%)	4,566 (95.1%)	0.0000	6,878 (94.2%)	6,881 (94.3%)	-0.004
ACS/unstable angina; n (%)	1,044 (41.8%)	1,017 (40.7%)	0.0223	1,795 (37.4%)	1,824 (38.0%)	-0.0124	2,839 (38.9%)	2,841 (38.9%)	0.000
Old MI; n (%)	351 (14.1%)	343 (13.7%)	0.0116	408 (8.5%)	423 (8.8%)	-0.0107	759 (10.4%)	766 (10.5%)	-0.003
Stable angina; n (%)	509 (20.4%)	506 (20.3%)	0.0025	716 (14.9%)	717 (14.9%)	0.0000	1,225 (16.8%)	1,223 (16.8%)	0.000
Coronary atherosclerosis and other forms of chronic ische	2,408 (96.4%)	2,407 (96.4%)	0.0000	4,455 (92.8%)	4,454 (92.8%)	0.0000	6,863 (94.0%)	6,861 (94.0%)	0.000
Ischemic stroke (w and w/o mention of cerebral infarction	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	000 (0.0%)	000 (0.0%)	#DIV/0!
TIA; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	000 (0.0%)	000 (0.0%)	#DIV/0!
Late effects of cerebrovascular disease; n (%)	5 (0.2%)	5 (0.2%)	0.0000	2 (0.0%)	3 (0.1%)	-0.0447	007 (0.1%)	008 (0.1%)	0.000
Heart failure (CHF); n (%)	433 (17.3%)	428 (17.1%)	0.0053	642 (13.4%)	641 (13.3%)	0.0029	1,075 (14.7%)	1,069 (14.6%)	0.003
Peripheral Vascular Disease (PVD) or PVD Surgery v2; n (%)	108 (4.3%)	117 (4.7%)	-0.0193	130 (2.7%)	135 (2.8%)	-0.0061	238 (3.3%)	252 (3.5%)	-0.011
Atrial fibrillation; n (%)	180 (7.2%)	170 (6.8%)	0.0157	194 (4.0%)	210 (4.4%)	-0.0199	374 (5.1%)	380 (5.2%)	-0.005
Other cardiac dysrhythmia; n (%)	799 (32.0%)	772 (30.9%)	0.0237	1,200 (25.0%)	1,244 (25.9%)	-0.0207	1,999 (27.4%)	2,016 (27.6%)	-0.004
Hemorrhagic stroke+Other cerebrovascular disease+Cereb	12 (0.5%)	12 (0.5%)	0.0000	13 (0.3%)	11 (0.2%)	0.0200	025 (0.3%)	023 (0.3%)	0.000
Other atherosclerosis+Cardiac conduction disorders+Other	883 (35.3%)	880 (35.2%)	0.0021	1,345 (28.0%)	1,355 (28.2%)	-0.0044	2,228 (30.5%)	2,235 (30.6%)	-0.002
Previous cardiac procedure (CABG or PTCA or Stent) + Hist	2,455 (98.3%)	2,459 (98.4%)	-0.0079	4,491 (93.5%)	4,482 (93.3%)	0.0081	6,946 (95.2%)	6,941 (95.1%)	0.005
Kidney-related conditions									
Occurrence of acute renal disease v2; n (%)	169 (6.8%)	179 (7.2%)	-0.0157	192 (4.0%)	182 (3.8%)	0.0103	361 (4.9%)	361 (4.9%)	0.000
Occurrence of hypertensive nephropathy; n (%)	160 (6.4%)	166 (6.6%)	-0.0081	133 (2.8%)	147 (3.1%)	-0.0177	293 (4.0%)	313 (4.3%)	-0.015
Occurrence of miscellaneous renal insufficiency v2; n (%)	131 (5.2%)	127 (5.1%)	0.0045	126 (2.6%)	137 (2.9%)	-0.0183	257 (3.5%)	264 (3.6%)	-0.005
Occurrence of chronic renal insufficiency w/o CKD (for PS)	115 (4.6%)	114 (4.6%)	0.0000	91 (1.9%)	101 (2.1%)	-0.0143	206 (2.8%)	215 (2.9%)	-0.006

Appendix B

Chronic kidney disease Stage 1-2 (for PS); n (%)	50 (2.0%)	52 (2.1%)	-0.0071	43 (0.9%)	47 (1.0%)	-0.0103	093 (1.3%)	099 (1.4%)	-0.009
CKD stage 3-6 + dialysis (for PS); n (%)	133 (5.3%)	123 (4.9%)	0.0182	108 (2.2%)	110 (2.3%)	-0.0067	241 (3.3%)	233 (3.2%)	0.006
Bladder stones+Kidney stones (for PS); n (%)	54 (2.2%)	52 (2.1%)	0.0069	92 (1.9%)	87 (1.8%)	0.0074	146 (2.0%)	139 (1.9%)	0.007
Urinary tract infections (UTIs); n (%)	104 (4.2%)	115 (4.6%)	-0.0195	150 (3.1%)	146 (3.0%)	0.0058	254 (3.5%)	261 (3.6%)	-0.005
Edema; n (%)	67 (2.7%)	78 (3.1%)	-0.0238	97 (2.0%)	98 (2.0%)	0.0000	164 (2.2%)	176 (2.4%)	-0.013
Other comorbidities									
COPD; n (%)	310 (12.4%)	306 (12.2%)	0.0061	324 (6.7%)	336 (7.0%)	-0.0119	634 (8.7%)	642 (8.8%)	-0.004
Asthma; n (%)	146 (5.8%)	162 (6.5%)	-0.0291	220 (4.6%)	215 (4.5%)	0.0048	366 (5.0%)	377 (5.2%)	-0.009
Obstructive sleep apnea; n (%)	259 (10.4%)	259 (10.4%)	0.0000	392 (8.2%)	412 (8.6%)	-0.0144	651 (8.9%)	671 (9.2%)	-0.010
Pneumonia; n (%)	87 (3.5%)	87 (3.5%)	0.0000	137 (2.9%)	127 (2.6%)	0.0183	224 (3.1%)	214 (2.9%)	0.012
Hyperthyroidism + Hypothyroidism + Other disorders of thy	278 (11.1%)	304 (12.2%)	-0.0343	429 (8.9%)	452 (9.4%)	-0.0173	707 (9.7%)	756 (10.4%)	-0.023
Liver disease; n (%)	3 (0.1%)	2 (0.1%)	0.0000	1 (0.0%)	1 (0.0%)	#DIV/0!	004 (0.1%)	003 (0.0%)	0.045
Osteoarthritis; n (%)	337 (13.5%)	342 (13.7%)	-0.0058	423 (8.8%)	424 (8.8%)	0.0000	760 (10.4%)	766 (10.5%)	-0.003
Other arthritis, arthropathies and musculoskeletal pain; n	768 (30.7%)	773 (30.9%)	-0.0043	1,282 (26.7%)	1,303 (27.1%)	-0.0090	2,050 (28.1%)	2,076 (28.4%)	-0.007
Dorsopathies; n (%)	534 (21.4%)	556 (22.3%)	-0.0218	872 (18.2%)	879 (18.3%)	-0.0026	1,406 (19.3%)	1,435 (19.7%)	-0.010
Fractures; n (%)	44 (1.8%)	52 (2.1%)	-0.0217	67 (1.4%)	67 (1.4%)	0.0000	111 (1.5%)	119 (1.6%)	-0.008
Falls v2; n (%)	29 (1.2%)	32 (1.3%)	-0.0090	28 (0.6%)	26 (0.5%)	0.0135	057 (0.8%)	058 (0.8%)	0.000
Osteoporosis; n (%)	63 (2.5%)	56 (2.2%)	0.0198	49 (1.0%)	40 (0.8%)	0.0212	112 (1.5%)	096 (1.3%)	0.017
Depression; n (%)	259 (10.4%)	241 (9.6%)	0.0267	320 (6.7%)	321 (6.7%)	0.0000	579 (7.9%)	562 (7.7%)	0.007
Anxiety; n (%)	323 (12.9%)	318 (12.7%)	0.0060	386 (8.0%)	391 (8.1%)	-0.0037	709 (9.7%)	709 (9.7%)	0.000
Sleep_Disorder; n (%)	153 (6.1%)	148 (5.9%)	0.0084	335 (7.0%)	333 (6.9%)	0.0039	488 (6.7%)	481 (6.6%)	0.004
Dementia; n (%)	34 (1.4%)	25 (1.0%)	0.0367	20 (0.4%)	24 (0.5%)	-0.0149	054 (0.7%)	049 (0.7%)	0.000
Delirium; n (%)	19 (0.8%)	19 (0.8%)	0.0000	19 (0.4%)	19 (0.4%)	0.0000	038 (0.5%)	038 (0.5%)	0.000
Psychosis; n (%)	11 (0.4%)	13 (0.5%)	-0.0149	17 (0.4%)	13 (0.3%)	0.0169	028 (0.4%)	026 (0.4%)	0.000
Use of medications									
Use of ACE inhibitors; n (%)	1,332 (53.3%)	1,316 (52.7%)	0.0120	2,689 (56.0%)	2,716 (56.6%)	-0.0121	4,021 (55.1%)	4,032 (55.2%)	-0.002
Use of ARBs; n (%)	486 (19.5%)	498 (19.9%)	-0.0101	879 (18.3%)	855 (17.8%)	0.0130	1,365 (18.7%)	1,353 (18.5%)	0.005
Use of Loop Diuretics - United; n (%)	193 (7.7%)	190 (7.6%)	0.0038	254 (5.3%)	286 (6.0%)	-0.0303	447 (6.1%)	476 (6.5%)	-0.016
Use of other diuretics- United; n (%)	98 (3.9%)	103 (4.1%)	-0.0102	188 (3.9%)	207 (4.3%)	-0.0202	286 (3.9%)	310 (4.2%)	-0.015
Use of nitrates-United; n (%)	1,089 (43.6%)	1,086 (43.5%)	0.0020	2,102 (43.8%)	2,128 (44.3%)	-0.0101	3,191 (43.7%)	3,214 (44.0%)	-0.006
Use of other hypertension drugs; n (%)	93 (3.7%)	94 (3.8%)	-0.0053	150 (3.1%)	163 (3.4%)	-0.0169	243 (3.3%)	257 (3.5%)	-0.011
Use of digoxin- United; n (%)	21 (0.8%)	20 (0.8%)	0.0000	18 (0.4%)	21 (0.4%)	0.0000	039 (0.5%)	041 (0.6%)	-0.014
Use of Anti-arrhythmics; n (%)	40 (1.6%)	42 (1.7%)	-0.0079	73 (1.5%)	74 (1.5%)	0.0000	113 (1.5%)	116 (1.6%)	-0.008
Use of COPD/asthma meds- United; n (%)	336 (13.5%)	315 (12.6%)	0.0267	529 (11.0%)	526 (11.0%)	0.0000	865 (11.8%)	841 (11.5%)	0.009
Use of statins; n (%)	2,267 (90.8%)	2,280 (91.3%)	-0.0175	4,415 (91.9%)	4,394 (91.5%)	0.0145	6,682 (91.5%)	6,674 (91.4%)	0.004
Use of other lipid-lowering drugs; n (%)	179 (7.2%)	189 (7.6%)	-0.0153	387 (8.1%)	408 (8.5%)	-0.0145	566 (7.8%)	597 (8.2%)	-0.015
Use of antiplatelet agents; n (%)	197 (7.9%)	217 (8.7%)	-0.0290	322 (6.7%)	359 (7.5%)	-0.0312	519 (7.1%)	576 (7.9%)	-0.030
Use of oral anticoagulants (Dabigatran, Rivaroxaban, Apixa	56 (2.2%)	58 (2.3%)	-0.0067	106 (2.2%)	113 (2.4%)	-0.0133	162 (2.2%)	171 (2.3%)	-0.007
Use of heparin and other low-molecular weight heparins;	6 (0.2%)	8 (0.3%)	-0.0200	0 (0.0%)	0 (0.0%)	#DIV/0!	006 (0.1%)	008 (0.1%)	0.000
Use of NSAIDs; n (%)	315 (12.6%)	339 (13.6%)	-0.0296	700 (14.6%)	702 (14.6%)	0.0000	1,015 (13.9%)	1,041 (14.3%)	-0.011
Use of oral corticosteroids; n (%)	386 (15.5%)	372 (14.9%)	0.0167	660 (13.7%)	671 (14.0%)	-0.0087	1,046 (14.3%)	1,043 (14.3%)	0.000
Use of bisphosphonate (United); n (%)	25 (1.0%)	22 (0.9%)	0.0103	20 (0.4%)	16 (0.3%)	0.0169	045 (0.6%)	038 (0.5%)	0.014
Use of opioids- United; n (%)	540 (21.6%)	533 (21.3%)	0.0073	998 (20.8%)	989 (20.6%)	0.0049	1,538 (21.1%)	1,522 (20.8%)	0.007
Use of antidepressants; n (%)	421 (16.9%)	409 (16.4%)	0.0134	746 (15.5%)	735 (15.3%)	0.0055	1,167 (16.0%)	1,144 (15.7%)	0.008
Use of antipsychotics; n (%)	22 (0.9%)	27 (1.1%)	-0.0201	36 (0.7%)	45 (0.9%)	-0.0225	058 (0.8%)	072 (1.0%)	-0.021
Use of anticonvulsants; n (%)	198 (7.9%)	199 (8.0%)	-0.0037	286 (6.0%)	296 (6.2%)	-0.0084	484 (6.6%)	495 (6.8%)	-0.008
Use of Benzos- United; n (%)	249 (10.0%)	247 (9.9%)	0.0033	457 (9.5%)	466 (9.7%)	-0.0068	706 (9.7%)	713 (9.8%)	-0.003
Use of anxiolytics/hypnotics- United; n (%)	128 (5.1%)	123 (4.9%)	0.0092	242 (5.0%)	240 (5.0%)	0.0000	370 (5.1%)	363 (5.0%)	0.005
Use of dementia meds- United; n (%)	15 (0.6%)	13 (0.5%)	0.0135	5 (0.1%)	7 (0.1%)	0.0000	020 (0.3%)	020 (0.3%)	0.000
Use of antiparkinsonian meds- United; n (%)	27 (1.1%)	31 (1.2%)	-0.0094	46 (1.0%)	38 (0.8%)	0.0212	073 (1.0%)	069 (0.9%)	0.010

Appendix B

Use of glucose test strips; n (%)	29 (1.2%)	31 (1.2%)	0.0000	58 (1.2%)	60 (1.2%)	0.0000	087 (1.2%)	091 (1.2%)	0.000
Use of thiazide- United; n (%)	192 (7.7%)	188 (7.5%)	0.0075	329 (6.9%)	317 (6.6%)	0.0120	521 (7.1%)	505 (6.9%)	0.008
Use of beta blockers; n (%)	2,164 (86.6%)	2,160 (86.5%)	0.0029	4,241 (88.3%)	4,252 (88.5%)	-0.0062	6,405 (87.7%)	6,412 (87.8%)	-0.003
Use of calcium channel blockers; n (%)	462 (18.5%)	460 (18.4%)	0.0026	780 (16.2%)	803 (16.7%)	-0.0135	1,242 (17.0%)	1,263 (17.3%)	-0.008
Use of aspirin; n (%)	312 (12.5%)	320 (12.8%)	-0.0090	798 (16.6%)	782 (16.3%)	0.0081	1,110 (15.2%)	1,102 (15.1%)	0.003
Use of Low Intensity Statins; n (%)	626 (25.1%)	633 (25.3%)	-0.0046	1,268 (26.4%)	1,257 (26.2%)	0.0045	1,894 (25.9%)	1,890 (25.9%)	0.000
Use of High Intensity Statins; n (%)	1,910 (76.5%)	1,892 (75.7%)	0.0188	3,661 (76.2%)	3,566 (74.3%)	0.0440	5,571 (76.3%)	5,458 (74.8%)	0.035
Use of Sympatomimetic agents; n (%)	27 (1.1%)	31 (1.2%)	-0.0094	46 (1.0%)	49 (1.0%)	0.0000	073 (1.0%)	080 (1.1%)	-0.010
Use of CNS stimulants; n (%)	5 (0.2%)	6 (0.2%)	0.0000	27 (0.6%)	27 (0.6%)	0.0000	032 (0.4%)	033 (0.5%)	-0.015
All antidiabetic medications except Insulin; n (%)	560 (22.4%)	587 (23.5%)	-0.0262	1,099 (22.9%)	1,109 (23.1%)	-0.0048	1,659 (22.7%)	1,696 (23.2%)	-0.012
DM Medications - Insulin Copy; n (%)	217 (8.7%)	219 (8.8%)	-0.0035	444 (9.2%)	454 (9.5%)	-0.0103	661 (9.1%)	673 (9.2%)	-0.003
Use of estrogens, progestins, androgens; n (%)	87 (3.5%)	93 (3.7%)	-0.0107	210 (4.4%)	216 (4.5%)	-0.0048	297 (4.1%)	309 (4.2%)	-0.005
Use of Angiogenesis inhibitors; n (%)	1 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	001 (0.0%)	000 (0.0%)	#DIV/0!
Use of Oral Immunosuppressants; n (%)	3 (0.1%)	3 (0.1%)	0.0000	10 (0.2%)	9 (0.2%)	0.0000	013 (0.2%)	012 (0.2%)	0.000
Use of fondaparinux or Bivalirudin; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	1 (0.0%)	#DIV/0!	000 (0.0%)	001 (0.0%)	#DIV/0!
Use of other direct thrombin inhibitors (Iepirudin, desirudin)	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	000 (0.0%)	000 (0.0%)	#DIV/0!
Use of CYP inhibitors; n (%)	406 (16.3%)	407 (16.3%)	0.0000	723 (15.1%)	743 (15.5%)	-0.0111	1,129 (15.5%)	1,150 (15.8%)	-0.008
Use of CYP inducers; n (%)	6 (0.2%)	8 (0.3%)	-0.0200	19 (0.4%)	16 (0.3%)	0.0169	025 (0.3%)	024 (0.3%)	0.000
Burden of disease/Healthcare utilization									
Combined comorbidity score, 180 days Copy									
...mean (sd)	1.19 (1.81)	1.21 (1.83)	-0.0110	0.60 (1.47)	0.61 (1.47)	-0.0068	0.80 (1.59)	0.82 (1.60)	-0.013
...median [IQR]	1.00 [0.00, 2.00]	1.00 [0.00, 2.00]	0.0000	0.00 [-1.00, 1.00]	0.00 [-1.00, 1.00]	0.0000	0.34 (1.59)	0.34 (1.60)	0.000
Frailty Score (mean): Empirical Version 365 days, v2									
...mean (sd)	0.18 (0.04)	0.18 (0.04)	0.0000	0.17 (0.03)	0.17 (0.03)	0.0000	0.17 (0.03)	0.17 (0.03)	0.000
...median [IQR]	0.17 [0.15, 0.20]	0.17 [0.15, 0.20]	0.0000	0.16 [0.14, 0.18]	0.16 [0.15, 0.18]	0.0000	0.16 (0.03)	0.16 (0.03)	0.000
Total N distinct ICD9/ICD10 diagnoses at the 3rd digit level									
...mean (sd)	8.40 (8.59)	8.76 (8.97)	-0.0410	6.01 (7.71)	6.05 (7.67)	-0.0052	6.83 (8.02)	6.98 (8.14)	-0.019
...median [IQR]	7.00 [0.00, 14.00]	8.00 [0.00, 14.00]	-0.1139	0.00 [0.00, 12.00]	0.00 [0.00, 12.00]	0.0000	2.40 (8.02)	2.74 (8.14)	-0.042
HAS-BLED Score (ICD-9 and ICD-10), 180 days									
...mean (sd)	3.43 (0.57)	3.43 (0.58)	0.0000	3.16 (0.46)	3.15 (0.45)	0.0220	3.25 (0.50)	3.25 (0.50)	0.000
...median [IQR]	3.00 [3.00, 4.00]	3.00 [3.00, 4.00]	0.0000	3.00 [3.00, 3.00]	3.00 [3.00, 3.00]	0.0000	3.00 (0.50)	3.00 (0.50)	0.000
number of different/distinct medication prescriptions									
...mean (sd)	8.75 (4.38)	8.77 (4.50)	-0.0045	8.58 (4.15)	8.63 (4.23)	-0.0119	8.64 (4.23)	8.68 (4.32)	-0.009
...median [IQR]	8.00 [6.00, 11.00]	8.00 [5.00, 11.00]	0.0000	8.00 [6.00, 11.00]	8.00 [6.00, 11.00]	0.0000	8.00 (4.23)	8.00 (4.32)	0.000
Any hospitalization within prior 30 days; n (%)	2,498 (100.0%)	2,498 (100.0%)	#DIV/0!	4,802 (100.0%)	4,802 (100.0%)	#DIV/0!	7,300 (100.0%)	7,300 (100.0%)	#DIV/0!
Number of Hospitalizations									
...mean (sd)	1.08 (0.30)	1.08 (0.32)	0.0000	1.06 (0.28)	1.06 (0.26)	0.0000	1.07 (0.29)	1.07 (0.28)	0.000
...median [IQR]	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	0.0000	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	0.0000	1.00 (0.29)	1.00 (0.28)	0.000
Number of hospital days									
...mean (sd)	3.61 (1.95)	3.60 (2.15)	0.0049	3.48 (2.00)	3.50 (1.64)	-0.0109	3.52 (1.98)	3.53 (1.83)	-0.005
...median [IQR]	3.00 [3.00, 4.00]	3.00 [3.00, 4.00]	0.0000	3.00 [3.00, 4.00]	3.00 [3.00, 4.00]	0.0000	3.00 (1.98)	3.00 (1.83)	0.000
Number of Emergency Department (ED) visits v3									
...mean (sd)	1.09 (1.26)	1.10 (1.37)	-0.0076	3.59 (5.64)	3.62 (6.71)	-0.0048	2.73 (4.63)	2.76 (5.50)	-0.006
...median [IQR]	1.00 [0.00, 1.00]	1.00 [0.00, 1.00]	0.0000	2.00 [0.00, 4.00]	2.00 [0.00, 4.00]	0.0000	1.66 (4.63)	1.66 (5.50)	0.000
Number of Office visits									
...mean (sd)	2.98 (3.14)	3.03 (3.30)	-0.0155	2.69 (2.85)	2.70 (2.91)	-0.0035	2.79 (2.95)	2.81 (3.05)	-0.007
...median [IQR]	2.00 [1.00, 4.00]	2.00 [1.00, 4.00]	0.0000	2.00 [1.00, 4.00]	2.00 [1.00, 4.00]	0.0000	2.00 (2.95)	2.00 (3.05)	0.000
Number of internal medicine/family medicine visits									
...mean (sd)	6.26 (8.89)	6.47 (10.55)	-0.0215	3.83 (5.90)	3.86 (6.58)	-0.0048	4.66 (7.07)	4.75 (8.16)	-0.012
...median [IQR]	3.00 [1.00, 8.00]	3.00 [1.00, 8.00]	0.0000	2.00 [0.00, 5.00]	2.00 [0.00, 5.00]	0.0000	2.34 (7.07)	2.34 (8.16)	0.000
Number of Cardiologist visits									

Appendix B

...mean (sd)	8.18 (5.00)	8.14 (5.05)	0.0080	1.00 (2.09)	1.02 (2.27)	-0.0092	3.46 (3.38)	3.46 (3.48)	0.000
...median [IQR]	8.00 [5.00, 11.00]	7.00 [5.00, 10.00]	0.1990	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.0000	2.74 (3.38)	2.40 (3.48)	0.099
Number electrocardiograms received v2									
...mean (sd)	3.33 (2.45)	3.33 (2.62)	0.0000	0.97 (1.32)	0.97 (1.36)	0.0000	1.78 (1.79)	1.78 (1.89)	0.000
...median [IQR]	3.00 [2.00, 4.00]	3.00 [2.00, 5.00]	0.0000	1.00 [0.00, 1.00]	1.00 [0.00, 1.00]	0.0000	1.68 (1.79)	1.68 (1.89)	0.000
Number of BNP tests									
...mean (sd)	0.11 (0.37)	0.10 (0.40)	0.0260	0.12 (0.37)	0.12 (0.38)	0.0000	0.12 (0.37)	0.11 (0.39)	0.026
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.0000	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.0000	0.00 (0.37)	0.00 (0.39)	0.000
Number of Cardiac biomarkers tests (troponin, CK-MBs, My									
...mean (sd)	0.68 (1.63)	0.73 (1.73)	-0.0297	0.72 (1.67)	0.73 (1.60)	-0.0061	0.71 (1.66)	0.73 (1.65)	-0.012
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 1.00]	0.0000	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.0000	0.00 (1.66)	0.00 (1.65)	0.000
Number of Ambulatory Blood pressure monitoring tests									
...mean (sd)	0.00 (0.03)	0.00 (0.02)	0.0000	0.00 (0.04)	0.00 (0.03)	0.0000	0.00 (0.04)	0.00 (0.03)	0.000
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.0000	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.0000	0.00 (0.04)	0.00 (0.03)	0.000
N of days on antihypertensive medications during baseline									
...mean (sd)	75.35 (78.69)	75.92 (78.36)	-0.0073	71.06 (77.53)	71.15 (77.62)	-0.0012	72.53 (77.93)	72.78 (77.87)	-0.003
...median [IQR]	31.00 [1.00, 168.00]	35.00 [1.00, 168.00]	-0.0509	14.00 [1.00, 163.00]	12.00 [1.00, 164.00]	0.0258	19.82 (77.93)	19.87 (77.87)	-0.001
N of days in database anytime prior									
...mean (sd)	1,658.31 (1,306.21)	1,660.85 (1,331.74)	-0.0019	1,989.48 (1,379.50)	1,998.92 (1,372.00)	-0.0069	1876.16 (1354.87)	1883.24 (1358.36)	-0.005
...median [IQR]	1,246.00 [612.00, 2,4	1,227.50 [593.75, 2,4	0.0140	1,682.50 [800.00, 3,0	1,693.00 [824.75, 3,0	-0.0076	1533.13 (1354.87)	1533.71 (1358.36)	0.000
Mean Copay for per prescription cost (charges in U.S. \$) (1									
...mean (sd)	23.00 (28.64)	23.95 (28.18)	-0.0334	16.82 (22.87)	16.49 (20.73)	0.0151	18.93 (24.99)	19.04 (23.55)	-0.005
...median [IQR]	14.98 [6.00, 29.47]	15.31 [6.44, 30.82]	-0.0116	10.69 [2.63, 22.50]	10.42 [2.98, 22.00]	0.0124	12.16 (24.99)	12.09 (23.55)	0.003
...Missing; n (%)	351 (14.1%)	361 (14.5%)	-0.0114	739 (15.4%)	743 (15.5%)	-0.0028	1,090 (14.9%)	1,104 (15.1%)	-0.006
Duration of index hospitalization (i.e. anchor hospitalizatio									
...mean (sd)	1.00 (0.00)	1.00 (0.00)	#DIV/0!	1.00 (0.00)	1.00 (0.00)	#DIV/0!	1.00 (0.00)	1.00 (0.00)	#DIV/0!
...median [IQR]	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	#DIV/0!	1.00 [1.00, 1.00]	1.00 [1.00, 1.00]	#DIV/0!	1.00 (0.00)	1.00 (0.00)	#DIV/0!
N of Generic name drugs									
...mean (sd)	12.43 (11.07)	12.50 (11.04)	-0.0063	10.82 (9.17)	10.89 (9.29)	-0.0076	11.37 (9.86)	11.44 (9.92)	-0.007
...median [IQR]	9.00 [5.00, 16.00]	9.00 [5.00, 16.00]	0.0000	8.00 [4.00, 14.00]	8.00 [4.00, 14.00]	0.0000	8.34 (9.86)	8.34 (9.92)	0.000
N of Brand name drugs									
...mean (sd)	3.15 (3.47)	3.17 (4.09)	-0.0053	3.53 (3.65)	3.59 (3.74)	-0.0162	3.40 (3.59)	3.45 (3.86)	-0.013
...median [IQR]	2.00 [1.00, 4.00]	2.00 [1.00, 4.00]	0.0000	2.00 [1.00, 4.00]	2.00 [1.00, 4.00]	0.0000	2.00 (3.59)	2.00 (3.86)	0.000
Number of D-dimer tests									
...mean (sd)	0.06 (0.26)	0.06 (0.26)	0.0000	0.07 (0.30)	0.07 (0.28)	0.0000	0.07 (0.29)	0.07 (0.27)	0.000
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.0000	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.0000	0.00 (0.29)	0.00 (0.27)	0.000
Numbe of CRP, high-sensitivity CRP tests									
...mean (sd)	0.05 (0.27)	0.04 (0.24)	0.0391	0.04 (0.25)	0.04 (0.24)	0.0000	0.04 (0.26)	0.04 (0.24)	0.000
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.0000	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.0000	0.00 (0.26)	0.00 (0.24)	0.000
Number of PT or aPTTt tests									
...mean (sd)	0.37 (1.05)	0.37 (1.00)	0.0000	0.39 (0.98)	0.40 (1.02)	-0.0100	0.38 (1.00)	0.39 (1.01)	-0.010
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.0000	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.0000	0.00 (1.00)	0.00 (1.01)	0.000
Number of Bleeding time tests									
...mean (sd)	0.00 (0.00)	0.00 (0.00)	#DIV/0!	0.00 (0.00)	0.00 (0.00)	#DIV/0!	0.00 (0.00)	0.00 (0.00)	#DIV/0!
...median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	#DIV/0!	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	#DIV/0!	0.00 (0.00)	0.00 (0.00)	#DIV/0!
Occurrence of creatinine tests ordered (for PS); n (%)	68 (2.7%)	68 (2.7%)	0.0000	119 (2.5%)	130 (2.7%)	-0.0126	187 (2.6%)	198 (2.7%)	-0.006
Cardiovascular stress test; n (%)	8 (0.3%)	5 (0.2%)	0.0200	10 (0.2%)	10 (0.2%)	0.0000	018 (0.2%)	015 (0.2%)	0.000
Echocardiogram; n (%)	1,774 (71.0%)	1,764 (70.6%)	0.0088	3,228 (67.2%)	3,232 (67.3%)	-0.0021	5,002 (68.5%)	4,996 (68.4%)	0.002
Colonoscopy; n (%)	79 (3.2%)	84 (3.4%)	-0.0112	178 (3.7%)	177 (3.7%)	0.0000	257 (3.5%)	261 (3.6%)	-0.005
Fecal occult blood (FOB) test; n (%)	67 (2.7%)	69 (2.8%)	-0.0061	114 (2.4%)	116 (2.4%)	0.0000	181 (2.5%)	185 (2.5%)	0.000
Flu vaccine; n (%)	348 (13.9%)	337 (13.5%)	0.0116	412 (8.6%)	404 (8.4%)	0.0072	760 (10.4%)	741 (10.2%)	0.007

Appendix B

Mammogram; n (%)	116 (4.6%)	120 (4.8%)	-0.0095	156 (3.2%)	168 (3.5%)	-0.0167	272 (3.7%)	288 (3.9%)	-0.010
Pap smear; n (%)	49 (2.0%)	49 (2.0%)	0.0000	100 (2.1%)	96 (2.0%)	0.0071	149 (2.0%)	145 (2.0%)	0.000
Pneumonia vaccine; n (%)	377 (15.1%)	400 (16.0%)	-0.0248	343 (7.1%)	331 (6.9%)	0.0078	720 (9.9%)	731 (10.0%)	-0.003
PSA test or Prostate exam for DRE; n (%)	380 (15.2%)	385 (15.4%)	-0.0056	621 (12.9%)	632 (13.2%)	-0.0089	1,001 (13.7%)	1,017 (13.9%)	-0.006
Bone mineral density; n (%)	39 (1.6%)	41 (1.6%)	0.0000	34 (0.7%)	32 (0.7%)	0.0000	073 (1.0%)	073 (1.0%)	0.000
Drug eluting stent; n (%)	826 (33.1%)	800 (32.0%)	0.0235	1,804 (37.6%)	1,804 (37.6%)	0.0000	2,630 (36.0%)	2,604 (35.7%)	0.006
Bare metal stent; n (%)	2,143 (85.8%)	2,146 (85.9%)	-0.0029	3,978 (82.8%)	3,958 (82.4%)	0.0106	6,121 (83.8%)	6,104 (83.6%)	0.005